Emeritus Professor Robert (Rob) Coleman

MBBS, MD, FRCP, FRCPE, FACP

School of Medicine and Population Health

Emeritus Professor of Medical Oncology

Professor Rob Coleman
Professor Rob Coleman
Profile picture of Professor Rob Coleman
r.e.coleman@sheffield.ac.uk
+44 114 230 5474
Broomcross Building, Floor 2, Cancer Clinical Trials Centre, Weston Park Hospital

Full contact details

Emeritus Professor Robert (Rob) Coleman
School of Medicine and Population Health
Broomcross Building, Floor 2, Cancer Clinical Trials Centre
Weston Park Hospital
Whitham Road
Sheffield
S10 2SJ
Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

Professor Robert (Rob) Coleman is Emeritus Professor of Medical Oncology at the University of Sheffield. He graduated in medicine from Kings College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991 where he was instrumental in developing clinical cancer research in the city and establishing an internationally respected bone oncology research team in Sheffield. Rob has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network. He has published over 450 peer-reviewed manuscripts and numerous book chapters, is a past-president of the Cancer and Bone Society and the founding editor of “Journal of Bone Oncology”.

Professor Coleman was Deputy Chair and on the Board of Trustees at St Luke’s Hospice (2010-2020), on the Board of Trustees for the national charity, Breast Cancer Campaign/Breast Cancer Now (2010-2018) and a Partner Governor on behalf of the University of Sheffield for the Council of Governors at Doncaster and Bassetlaw NHS Foundation Trust (2017-2020). He remains a Board member for Weston Park Cancer Charity (since 2014) and is Chair of Governors at Clifford All Saints Primary School. 

From 2014-2019 Professor Coleman was a part-time Medical Director for the global independent medical education provider, prIME Oncology™, developing and delivering both live and on-line educational activities for oncologists and other providers of cancer care. Since retiring from his formal position at the university in 2017, he remains research active, lectures on his areas of expertise around the world and provides consultancy to a range of pharma and biotech companies developing new oncology treatments.

Publications

Show: Featured publications All publications

Journal articles

  • Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J , Taylor C et al (2022) . Journal of Bone Oncology, 35, 100442-100442.
  • Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2021) . Physiological Reviews, 101(3), 797-855.
  • Rachner TD, Coleman R, Hadji P & Hofbauer LC (2021) . Journal of Bone and Mineral Research, 36(10), 1906-1913.
  • Coleman R, Hadji P, Body J-J, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A , Van Poznak C et al (2020) . Annals of Oncology, 31(12), 1650-1663.
  • Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I , Sohn J et al (2020) . The Lancet Oncology, 21(1), 60-72.
  • Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D , Bowman A et al (2018) . Journal of Bone Oncology, 13, 123-135.
  • Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero J-C , Rojo F et al (2017) . The Lancet Oncology, 18(11), 1543-1552.
  • Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J & Cameron D (2015) . The Lancet, 386(10001), 1353-1361.
  • Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R , Barrett-Lee P et al (2014) . The Lancet Oncology, 15(9), 997-1006.
  • Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M , Widmark A et al (2013) . NEW ENGLAND JOURNAL OF MEDICINE, 369(3), 213-223.
  • Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C , Frassoldati A et al (2013) . Ann Oncol, 24(2), 398-405.
  • Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ , Ritchie D et al (2011) . N Engl J Med, 365(15), 1396-1405.

Book chapters

  • Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020) Springer Science and Business Media LLC

All publications

Books

  • (2005) . Wiley.

Journal articles

  • Savage P, Froeling F, Lythgoe M, Fisher R, Maher G, Winter M, Eremeishvili K, Sarwar N, Aguiar X, Singh K , Hancock B et al (2025) . Journal of Obstetrics and Gynaecology, 45(1).
  • Hadji P, Aapro M, Al-Dagri N, Alokail M, Biver E, Body J-J, Brandi ML, Brown J, Confavreux C, Cortet B , Drake M et al (2025) . Journal of Bone Oncology, 100694-100694.
  • Kong X, Liu Q, Qu Z, Wang X, Zhang W, Liu Y, Coleman R, Lin C & Wang J (2025) . Cancer Innovation, 4(5).
  • Coleman R (2024) . Journal of Bone Oncology, 100658-100658.
  • Brown J, Paggiosi M, Rathbone E, Dodwell D, Cameron D, Gregory W, Eastell R & Coleman R (2024) . Journal of Bone Oncology, 45, 100529-100529.
  • (2024) . Cancer Innovation, 3(1).
  • Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E , Siegel JM et al (2024) . Breast Cancer Research and Treatment, 204(2), 249-259.
  • Coleman R (2024) . Annals of Translational Medicine, 12(4), 60-60.
  • Taylor C, Dodwell D, McGale P, Hills RK, Berry R, Bradley R, Braybrooke J, Clarke M, Gray R, Holt F , Liu Z et al (2023) . The Lancet, 402(10416), 1991-2003.
  • Velikova G, Morden JP, Haviland JS, Emery C, Barrett-Lee P, Earl H, Bloomfield D, Brunt AM, Canney P, Coleman R , Verrill M et al (2023) . The Lancet Oncology, 24(12), 1359-1374.
  • Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell’Orto P, Biasi O, Degasperi A, Brown LC, Láng I , MacGrogan G et al (2023) . Annals of Oncology, 34(4), 397-409.
  • Robertson JFR, Coleman RE, Cheung K-L, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K , Rauchhaus P et al (2022) . Clinical Cancer Research, 28(24), 5469-5469.
  • Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J , Taylor C et al (2022) . Journal of Bone Oncology, 35, 100442-100442.
  • Coleman RE, Paterson AHG & Gomis RR (2022) . Annals of Oncology, 33, S152-S152.
  • Rugo HS, Drumea K, Lee SC, Campone M, Van Poznak C, Neven P, Vega Alonso E, Naume B, Siegel JM, Li R , Uema D et al (2022) . Annals of Oncology, 33, S211-S212.
  • Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, Scagliotti GV, Shimizu K & Stopeck A (2022) . Journal of Bone Oncology, 100416-100416.
  • Coleman R, Chan A, Barrios C, Cameron D, Costa L, Dowsett M, Harrison D, Howell A, Lacombe D, MacKenzie M , Martin M et al (2022) . The Lancet Oncology, 23(3), e89-e90.
  • Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, Peto R, Dodwell D, McGale P, Taylor C , Francis PA et al (2022) . The Lancet Oncology, 23(3), 382-392.
  • Goyal A, Mann GB, Fallowfield L, Duley L, Reed M, Dodwell D, Coleman RE, Fakis A, Newcombe R, Jenkins V , Whitham D et al (2021) . BMJ Open, 11(12).
  • Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Peto R, Davies L, Dodwell D, McGale P, Pan H , Taylor C et al (2021) . The Lancet Oncology, 22(8), 1139-1150.
  • Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2021) . Physiological Reviews, 101(3), 797-855.
  • Rachner TD, Coleman R, Hadji P & Hofbauer LC (2021) . Journal of Bone and Mineral Research, 36(10), 1906-1913.
  • D'Oronzo S, Gregory W, Nicholson S, Chong YK, Brown J & Coleman R (2021) . Journal of Bone Oncology, 28, 100367.
  • Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, Neven P, Stierer M, Holcombe C, Coleman R , Forbes J et al (2021) . Cancer Research, 81(4_Supplement).
  • Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) . Cancer Research, 81(4_Supplement).
  • Sestak I, Blake G, Patel R, Cuzick J, Howell A, Coleman R & Eastell R (2021) . British Journal of Cancer.
  • Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Fearnside J, Coleman RE & Greenfield DM (2021) . Supportive Care in Cancer, 29(2), 1145-1145.
  • Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A , MacPherson I et al (2020) . Trials, 21(1).
  • Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C , Collinson FJ et al (2020) . Journal of Bone Oncology, 25.
  • Coleman R, Hadji P, Body J-J, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A , Van Poznak C et al (2020) . Annals of Oncology, 31(12), 1650-1663.
  • Coleman R (2020) . Bone.
  • D'Oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Cives M, Tucci MG, Stucci LS, Coleman RE & Silvestris F (2020) . Annals of Oncology, 31, S26-S26.
  • Robertson JFR, Coleman RE, Cheung K-L, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K , Rauchhaus P et al (2020) . Clinical Cancer Research, 26(7), 1574-1585.
  • Savage P, Winter M, Parker V, Harding V, Sita‐Lumsden A, Fisher RA, Harvey R, Unsworth N, Sarwar N, Short D , Aguiar X et al (2020) . BJOG: An International Journal of Obstetrics & Gynaecology.
  • Coleman R, Zhou Y & Chan A (2020) . The Lancet Oncology, 21(3), e125-e125.
  • Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M , Press MF et al (2020) . Clinical Breast Cancer.
  • Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I , Sohn J et al (2020) . The Lancet Oncology, 21(1), 60-72.
  • Mahtani R, Holmes F-A, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M , Press MF et al (2020) . Clinical Breast Cancer, 20(3), e251-e260.
  • Walsh JS, Marshall H, Smith IL, Greenfield DM, Swain J, Best E, Ashton J, Brown JM, Huddart R, Coleman RE , Snowden JA et al (2019) . PLOS Medicine, 16(11).
  • Coleman R (2019) . The Breast, 48(Supplement 1), S92-S96.
  • Danson S, Mulvey MR, Turner L, Horsman J, Escott KJ, Coleman RE, Ahmedzai SH, Bennett MI & Andrew D (2019) . Journal of Bone Oncology.
  • Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J & Eastell R (2019) . Bone, 124, 83-88.
  • Gray R, Bradley R, Braybrooke J, Liu Z, Peto R, Davies L, Dodwell D, McGale P, Pan H, Taylor C , Barlow W et al (2019) . The Lancet, 393(10179), 1440-1452.
  • D'Oronzo S, Coleman R, Brown J & Silvestris F (2019) . Journal of Bone Oncology, 15.
  • Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva M , Dunning MJ et al (2019) . The Journal of Pathology, 247(3), 381-391.
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) . Clinical Cancer Research, 25(9), 2769-2782.
  • Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE & Greenfield DM (2019) . Supportive Care in Cancer, 27(5), 1755-1763.
  • Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D , Bowman A et al (2018) . Journal of Bone Oncology, 13, 123-135.
  • Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider M-T, Rhee CS, Qin Y, Gregory WM , Garrido-Castro AC et al (2018) . American Journal of Cancer, 78(18), 5300-5314.
  • Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G , Maccon K et al (2018) . JNCI: Journal of the National Cancer Institute, 110(8), 871-879.
  • Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ , Bonnefoi HR et al (2018) . New England Journal of Medicine, 379(2), 122-137.
  • Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J , Schneeweiss A et al (2018) . Annals of Oncology, 29(8), 1763-1770.
  • Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M & Vogel C (2018) . Breast Cancer Research and Treatment, 171(1), 11-20.
  • Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, Dodwell D & Coleman R (2018) . European Journal of Cancer, 94, 70-78.
  • Logothetis C, Morris MJ, Den R & Coleman RE (2018) . Cancer and Metastasis Reviews, 37(1), 189-196.
  • Handforth C, D’Oronzo S, Coleman R & Brown J (2018) . Calcified Tissue International, 102(2), 251-264.
  • Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M , Rugo H et al (2018) . Breast Cancer Research and Treatment, 169(1), 1-7.
  • Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G , Bradley R et al (2018) . The Lancet Oncology, 19(1), 27-39.
  • Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R & Wyld L (2018) . PharmacoEconomics, 36(1), 29-38.
  • Rachner TD, Coleman R, Hadji P & Hofbauer LC (2018) . The Lancet Diabetes & Endocrinology, 6(11), 901-910.
  • Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A , Wiechno P et al (2018) . European Urology, 73(3), 427-435.
  • Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH , Gnant M et al (2017) . The Lancet Oncology, 18(12), 1688-1700.
  • Anderson RA, Mansi J, Coleman RE, Adamson DJA & Leonard RCF (2017) . European Journal of Cancer, 87, 58-64.
  • D’Oronzo S, Brown J & Coleman R (2017) . Journal of Bone Oncology, 9, 1-9.
  • Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero J-C , Rojo F et al (2017) . The Lancet Oncology, 18(11), 1543-1552.
  • Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D , Brunt AM et al (2017) . The Lancet Oncology, 18(7), 929-945.
  • D'Oronzo S, Brown J & Coleman R (2017) . European Journal of Cancer Care.
  • Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R , O'Reilly S et al (2017) . The Lancet Oncology, 18(6), 755-769.
  • Hadji P, Aapro MS, Body J-J, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer C-C, de Villiers T, Baber R , Roodman GD et al (2017) . Journal of Bone Oncology, 7, 1-12.
  • Dodwell D, Richmond A, Hazell S & Coleman R (2017) . Clinical Oncology, 29(9), 550-552.
  • Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE , Ortmann O et al (2017) . Journal of Clinical Oncology, 35(22), 2507-2514.
  • Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE & Anderson RA (2017) . Annals of Oncology, 28(8), 1811-1816.
  • Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S, Wilhelm S , Xu L et al (2017) . Annals of Oncology, 28(5), 1090-1097.
  • Shore ND, Nilsson S, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Heinrich D, Bottomley D, Hoskin P, Franzen L , Solberg A et al (2017) . Journal of Urology, 197(4S).
  • Nilsson S, Sartor AO, Vogelzang NJ, Coleman RE, O'Sullivan JM, Shore ND, Heinrich D, Bottomley D, Hoskin P, Franzen L , Solberg A et al (2017) . Journal of Clinical Oncology, 35(6_suppl), 177-177.
  • Coleman R, Collinson M, Bell R, Marshall H, Dodwell D, Keane M, Gil M, Gregory W & Cameron D (2017) . Cancer Research, 77(4_Supplement).
  • Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM & Coleman RE (2017) . European Journal of Cancer, 71, 1-6.
  • Baselga J, Coleman RE, Cortés J & Janni W (2017) . Critical Reviews in Oncology/Hematology, 119, 113-122.
  • Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Widmark A, Thuresson M, Xu L, Germino J & Sartori O (2017) . Clinical Genitourinary Cancer, 15(1), 42-52.
  • Body JJ, Terpos E, Tombal B, Hadji P, Arif A, Young A, Aapro M & Coleman R (2016) . Cancer Treatment Reviews, 51, 46-53.
  • Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R , Seger MA et al (2016) . European Urology, 70(5), 875-883.
  • Wilson C, Hinsley S, Marshall H, Cameron D, Bell R, Dodwell D & Coleman RE (2016) . Journal of Bone Oncology.
  • Winter MC, Tidy JA, Hills A, Ireson J, Gillett S, Singh K, Hancock BW & Coleman RE (2016) . Gynecol Oncol.
  • Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE & Ottewell P (2016) . Oncotarget, 7, 75571-75584.
  • Coleman R (2016) . Journal of Bone Oncology, 5(3), 90-92.
  • Coleman RE (2016) Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer. Oncology, 30(8), 695-702.
  • Macdonald MC, Hancock BW, Winter MC, Coleman RE & Tidy JA (2016) Management and outcomes of patients with stage I and III low-risk gestational trophoblastic neoplasia treated in Sheffield, UK, from 1997–2006. Journal of Reproductive Medicine, 61(4), 341-346.
  • Schmidt N, Jacob L, Coleman R, Kostev K & Hadji P (2016) . Breast Cancer Research and Treatment, 157(2), 401-401.
  • Coleman RE, Li R, Sawhney AG, Petrenciuc O & Rugo HS (2016) . Journal of Clinical Oncology, 34(15_suppl), TPS622-TPS622.
  • Rugo HS, Li R, Petrenciuc O, Zhang A & Coleman RE (2016) . Journal of Clinical Oncology, 34(15_suppl), TPS621-TPS621.
  • Taylor F, Short D, Harvey R, Winter MC, Tidy J, Hancock BW, Savage PM, Sarwar N, Seckl MJ & Coleman RE (2016) . BJOG: An International Journal of Obstetrics & Gynaecology, 123(7), 1175-1181.
  • Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M & Parker C (2016) . The Prostate, 76(10), 905-916.
  • Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Reuning-Scherer J, Shan M, Zhan L & Parker C (2016) . Annals of Oncology, 27(5), 868-874.
  • Wilson C & Coleman R (2016) . JAMA Oncology, 2(4), 423-423.
  • Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) . Journal of the National Cancer Institute, 108(4).
  • Wilson C, Gossiel F, Leonard R, Anderson RA, Adamson DJA, Thomas G & Coleman RE (2016) . Journal of Bone Oncology, 5(1), 43-49.
  • Coleman R (2016) . Seminars in Nuclear Medicine, 46(2), 99-104.
  • Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M , Holcombe C et al (2016) . The Lancet, 387(10021), 866-873.
  • Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz J-MA, O’Shaughnessy J, Beck RM, Ko A , Renschler MF et al (2016) . Trials, 17(1).
  • Gregory WM, Twelves CJ, Bell R, Smye SW, Howard DR, Coleman RE & Cameron DA (2016) . Breast Cancer Research and Treatment, 155(2), 303-311.
  • Baird R, Banks I, Cameron D, Chester J, Earl H, Flannagan M, Januszewski A, Kennedy R, Payne S, Samuel E , Taylor H et al (2016) . Ecancermedicalscience, 10, 608-608.
  • Macdonald MC, Hancock BW, Winter MC, Coleman RE & Tidy JA (2016) Management and Outcomes of Patients with Stage I and IlIl Low-Risk Gestational Trophoblastic Neoplasia Treated in Sheffield, UK, from 1997-2006.. J Reprod Med, 61(7-8), 341-346.
  • Schimdt N, Jacob L, Coleman R, Kostev K & Hadji P (2016) . Breast Cancer Research and Treatment, 155(1), 151-157.
  • Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) . Annals of Oncology, 27(3), 379-390.
  • Greenfield DM, Blewitt A, Coleman RE, Walsh JS, Snowden JA, Ross RJM & Han TS (2016) . Clinical Endocrinology, 84(2), 296-304.
  • Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz J-MA, O’Shaughnessy J, Beck RM, Ko A , Renschler MF et al (2015) . Trials, 16.
  • Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H , Brain E et al (2015) . Annals of Oncology, 26(12), 2505-2506.
  • Coleman R (2015) . The Breast, 24, S21-S21.
  • (2015) . The Lancet, 386(10001), 1341-1352.
  • Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J & Cameron D (2015) . The Lancet, 386(10001), 1353-1361.
  • Amadori D, Rossetti C, Aglietta M, Messina C, Versari A, Vogelzang NJ, Sartor A, Coleman RE, Govi S, Fang F , Skjorestad I et al (2015) . Annals of Oncology, 26, vi54-vi54.
  • Velikova G, Morden J, Barrett-Lee P, Bloomfield D, Brunt M, Canney P, Coleman R, Russel S, Verrill M, Wardley A , Bliss J et al (2015) Quality of Life (QOL) Results of the UK TACT2 Trial: More Intensive Chemotherapy for Early Breast Cancer (EBC) Has a Measurable Impact on Patient-Reported Symptoms and Functioning (CRUK/05/019). QUALITY OF LIFE RESEARCH, 24, 91-91.
  • Wedel SA, Mellado B, Sartor O, Vogelzang N, Hoskin P, Nilsson S, Coleman R, Parker C, Wahba M, Haugen I & Shore N (2015) Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC) patients with symptomatic bone metastases included in the phase 3 ALSYMPCA trial. Oncology Research and Treatment, 38, 267-267.
  • Pavlovic M, Arnal-Estapé A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albéniz X, Morales M, Urosevic J , Gawrzak S et al (2015) . Journal of the National Cancer Institute, 107(12), djv256-djv256.
  • Price JM, Lo C, Abdi S, Winter MC, Coleman RE, Tidy J & Hancock BW (2015) . International Journal of Gynecologic Cancer, 25(9), 1731-1736.
  • Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O & Saad F (2015) . European Urology, 68(5), 850-858.
  • Coleman R & Hadji P (2015) . The Lancet, 386(9992), 409-410.
  • Talari ACS, Evans CA, Holen I, Coleman RE & Rehman IU (2015) . Journal of Raman Spectroscopy, 46(5), 421-427.
  • Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S , Shepherd LE et al (2015) . Journal of Clinical Oncology, 33(14), 1574-1583.
  • Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H , Brain E et al (2015) . Annals of Oncology, 26(5), 873-879.
  • Wilson C, Ottewell P, Coleman RE & Holen I (2015) . BMC Cancer, 15(1).
  • Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H , Braun A et al (2015) . Annals of Oncology, 26(2), 368-374.
  • Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D’Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C , Goossen H et al (2015) . Journal of Immunotherapy, 38(2), 71-76.
  • Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ , Martino S et al (2015) . New England Journal of Medicine, 372(5), 436-446.
  • Taylor F, Short D, Winter MC, Tidy J, Savage PM, Sarwar N, Hancock BW, Seckl MJ & Coleman RE (2015) . Gynecologic Oncology, 136(2), 258-263.
  • Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A & Eastell R (2014) . The Lancet Oncology, 15(13), 1460-1468.
  • Mellado B, Sartor O, Vogelzang NJ, Hoskin P, Nilsson S, Coleman RE, Parker C, Wahba M, Haugen I & Shore ND (2014) . European Urology Supplements, 13(5), 138-138.
  • Kuczyk M, Parker C, Vogelzang N, Sartor O, Bottomley D, Coleman R, Skjorestad I, Whaba M & Nilsson S (2014) 1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study. ONCOLOGY RESEARCH AND TREATMENT, 37, 178-178.
  • Wedel S, Wiechno P, Helle SI, Logue J, Nilsson S, Sartor O, Coleman RE, Kliment J, Fang F & Parker C (2014) Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group. ONCOLOGY RESEARCH AND TREATMENT, 37, 86-87.
  • Goyal A, Dodwell D, Reed MW & Coleman RE (2014) . Journal of Clinical Oncology, 32(34), 3902-3902.
  • Logue J, Wedel S, Chodacki A, Sartor O, Nilsson S, Coleman RE, James N, Aksnes A, Wahba M & Parker C (2014) . Annals of Oncology, 25, iv264-iv264.
  • Conte PF, Yardley DA, Brufsky A, Coleman RE, Cortes J, Gluck S, Nabholtz J, O'shaughnessy J, Li L, Miller J , Barton D et al (2014) . Annals of Oncology, 25, iv135-iv135.
  • Ireson J, Singh K, Gillett S, Hills A, Everard J, Winter M, Coleman RE, Tidy J & Hancock BW (2014) Evolution of a specialist gestational trophoblastic disease service with a major nursing component: The Sheffield, United Kingdom, experience. Journal of Reproductive Medicine, 59(3), 195-198.
  • Coleman R, Aksnes A-K, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M & Flamen P (2014) . Breast Cancer Research and Treatment, 145(2), 411-418.
  • Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J , Widmark A et al (2014) . The Lancet Oncology, 15(7), 738-746.
  • Renton T, Taylor T, Popat S, Popat R, Sivardeen Z, Fogelman I, Hawkesford A, Ruggiero S, Rogers S, Leyland S & Coleman R (2014) . British Dental Journal, 216(9), 488-489.
  • Coleman R, Body JJ, Aapro M, Hadji P & Herrstedt J (2014) . Annals of Oncology, 25, iii124-iii137.
  • Fizazi K, Coleman R, Klotz L, Pittman K, Milecki P, Costa L, Von Moos R, Ganju V, Wei R, Demonty G , Braun A et al (2014) . European Urology Supplements, 13(1), e869-e869a.
  • Shore N, Sartor O, Vogelzang N, Hoskin P, Nilsson S, Coleman R, Parker C, Wahba M & Staudacher K (2014) . Journal of Urology, 191(4S).
  • Saxton JM, Scott EJ, Daley AJ, Woodroofe MN, Mutrie N, Crank H, Powers HJ & Coleman RE (2014) . Breast Cancer Research, 16(2).
  • Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) . Endocr Relat Cancer, 21(2), 327-341.
  • EBCTCG (Early Breast Cancer Trialists' Collaborative Group) (2014) . The Lancet, 383(9935), 2127-2135.
  • Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R , Barrett-Lee P et al (2014) . The Lancet Oncology, 15(9), 997-1006.
  • Ireson J, Singh K, Gillett S, Hills A, Everard J, Winter M, Coleman RE, Tidy J & Hancock BW (2014) Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experience.. J Reprod Med, 59(5-6), 195-198.
  • Popescu RA, Schaefer R, Califano R, Eckert R, Coleman R, Douillard J-Y, Cervantess A, Casali PG, Sessa C, Van Cutsem E , de Vries E et al (2014) . ANNALS OF ONCOLOGY, 25(1), 9-15.
  • Agarwal R, Alifrangis C, Everard J, Savage PM, Short D, Tidy J, Fisher RA, Sebire NJ, Harvey R, Hancock BW , Coleman RE et al (2014) Management and Survival of Patients with FIGO High-risk Gestational Trophoblastic Neoplasia. JOURNAL OF REPRODUCTIVE MEDICINE, 59(1-2), 7-12.
  • Hofbauer LC, Rachner TD, Coleman RE & Jakob F (2014) . The Lancet Diabetes and Endocrinology.
  • Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G & Murray N (2014) . Lancet Oncol, 15(1), 114-122.
  • Thompson J, Coleman R, Colwell B, Freeman J, Greenfield D, Holmes K, Mathers N & Reed M (2014) . Eur J Oncol Nurs, 18(1), 10-16.
  • Nilsson S, Schrader AJ, Kliment J, Solberg A, Franzén L, Bottomley D, Syndikus I, Parker C, Sartor O, Skjørestad I , Jensen T et al (2013) . European Urology Supplements, 12(6), 178-178.
  • Gregory W, Marshall H, Cameron D, Twelves C, Bell R & Coleman R (2013) . Trials, 14(S1).
  • Coleman R, Hinsley S, Bell R, Cameron D, Dodwell D, Liversedge V, Burkinshaw R, Keane M, Gil M & Marshall H (2013) Adjuvant therapy in early breast cancer with zoledronic acid (AZURE - BIG 01/04): Final efficacy analysis. EUROPEAN JOURNAL OF CANCER, 49, S5-S5.
  • Coleman RE, Gregory W, Marshall H, Wilson C & Holen I (2013) . Breast, 22 Suppl 2, S50-S56.
  • Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M , Widmark A et al (2013) . NEW ENGLAND JOURNAL OF MEDICINE, 369(3), 213-223.
  • Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R , Jyothirmayi R et al (2013) . J Clin Oncol, 31(21), 2685-2691.
  • Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N , Smith M et al (2013) . Journal of Bone Oncology, 2(2), 70-76.
  • Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Ding B, Maniar T & Coleman RE (2013) . Journal of Clinical Oncology, 31(15_suppl), TPS662-TPS662.
  • Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, Fisher RA, Short D, Casalboni S, Catalano K & Seckl MJ (2013) . JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 33(4), 406-411.
  • Young RJ & Coleman RE (2013) . Future Oncol, 9(5), 633-643.
  • Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S , Holen I et al (2013) . Clin Cancer Res, 19(10), 2755-2765.
  • Coleman RE, Rathbone E & Brown JE (2013) . Nat Rev Rheumatol, 9(6), 365-374.
  • Patrick D, Smith MR, Cleeland C, Fallowfield L, Tombal B, Oudard S, Shore N, Saad F, Marx G, Coleman R , Gómez-Veiga F et al (2013) . European Urology Supplements, 12(1), e99-e100.
  • Vogelzang NJ, Parker C, Nilsson S, Coleman RE, O'Bryan-Tear CG, Shan M & Sartor AO (2013) . Journal of Clinical Oncology, 31(6_suppl), 11-11.
  • Coleman R & Hadji P (2013) . Journal of Bone Oncology, 2(1), 1-1.
  • Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T , Hainsworth J et al (2013) . LANCET ONCOLOGY, 14(1), 72-80.
  • Aapro M, van de Velde CJH, Putter H, Markopoulos C, Bartlett JMS & Coleman RE (2013) . Breast.
  • Awada A, Garcia AA, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ , Cocquyt V et al (2013) . The Lancet Oncology.
  • Hadji P, Coleman R & Gnant M (2013) . Critical Reviews in Oncology/Hematology.
  • Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN & Galsky MD (2013) . European Urology.
  • Taylor F, Grew T, Everard J, Ellis L, Winter MC, Tidy J, Hancock BW & Coleman RE (2013) . European Journal of Cancer.
  • Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Rebecca A, Tevaarwerk AJ, Swenson K, Lind P & Mauri D (2013) . Oncologist, 18(4), 353-361.
  • Coleman R (2013) . JOURNAL OF UROLOGY, 189(1), S57-S58.
  • Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C , Frassoldati A et al (2013) . Ann Oncol, 24(2), 398-405.
  • Thompson J, Coleman R, Colwell B, Freeman J, Greenfield D, Holmes K, Mathers N & Reed M (2013) . Psychooncology, 22(8), 1866-1871.
  • Winter MC & Coleman RE (2013) . Clin Oncol (R Coll Radiol), 25(2), 135-145.
  • Scott E, Daley AJ, Doll H, Woodroofe N, Coleman RE, Mutrie N, Crank H, Powers HJ & Saxton JM (2013) . Cancer Causes Control, 24(1), 181-191.
  • Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, Gregory WM, Cameron D & Bell R (2012) . General Session Abstracts.
  • Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Ke C, Maniar T & Coleman RE (2012) . Ongoing Trials Poster Session Abstracts.
  • Barrett-Lee PJ, Casbard A, Abraham J, Grieve R, Wheatley D, Simmons P, Coleman R, Hood K, Griffiths G & Murray N (2012) . Poster Discussion Abstracts.
  • Wilson C, Winter MC, Holen I, Freeman JV, Evans AC & Coleman RE (2012) . Poster Session Abstracts.
  • Cameron D, Barrett-Lee P, Canney P, Banerji J, Bartlett J, Bloomfield D, Bowden S, Brunt M, Earl H, Ellis P , Fletcher M et al (2012) . General Session Abstracts.
  • Bliss JM, Ellis P, Kilburn L, Bartlett J, Bloomfield D, Cameron D, Canney P, Coleman RE, Dowsett M, Earl H , Verril M et al (2012) . Poster Session Abstracts.
  • Hadji P, Coleman R, Gnant M & Green JR (2012) . Annals of Oncology, 23(11), 2782-2790.
  • Brown JE, Cook RJ, Lipton A & Coleman RE (2012) . Clin Cancer Res, 18(22), 6348-6355.
  • Wilson C, Holen I & Coleman RE (2012) . Cancer Treat Rev, 38(7), 877-889.
  • Sartor O, Coleman RE, Nilsson S, Vogelzang N, Cross A, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas JE, Zou J & Parker C (2012) . Annals of Oncology, 23, ix308-ix309.
  • Parker C, Coleman RE, Nilsson S, Vogelzang N, Lloyd AJ, Staudacher K, van Gool R & Sartor AO (2012) . Annals of Oncology, 23, ix296-ix296.
  • Coleman RE, Barrios C, Bell R, Finkelstein DM, Iwata H, Martin M, Braun A, Ke C, Maniar T & Goss PE (2012) . Annals of Oncology, 23, ix115-ix115.
  • Lester JE, Dodwell D, BrownJ.E. , Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM & Coleman RE (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. Journal of Bone Oncology, 1(2), 57-62.
  • Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2012) A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. Journal of Bone Oncology, 1(2), 47-56.
  • Coleman RE (2012) . Curr Opin Support Palliat Care, 6(3), 322-329.
  • Coleman R, Gnant M, Morgan G & Clezardin P (2012) . J Natl Cancer Inst, 104(14), 1059-1067.
  • Kingdon SJ, Coleman RE, Ellis L & Hancock BW (2012) Deaths from gestational trophoblastic neoplasia: any lessons to be learned?. J Reprod Med, 57(7-8), 293-296.
  • Coleman R & Hadji P (2012) . Journal of Bone Oncology, 1(1), 1.
  • Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP-K, Hayward L, Simmonds P, Waterhouse A & Marshall H (2012) . Journal of Clinical Oncology, 30(15_suppl), 511-511.
  • Marshall H, Gregory W, Bell R, Cameron DA, Dodwell DJ, Keane MM, Gil Gil MJ, Davies C & Coleman RE (2012) . Journal of Clinical Oncology, 30(15_suppl), 502-502.
  • Sartor AO, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A, Johannessen DC , Nilsson S et al (2012) . Journal of Clinical Oncology, 30(15_suppl), 4551-4551.
  • Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A , Johannessen DC et al (2012) . Journal of Clinical Oncology, 30(15_suppl), LBA4512-LBA4512.
  • Gregory W, Marshall H, Bell R, Cameron DA & Coleman RE (2012) . Journal of Clinical Oncology, 30(15_suppl), 513-513.
  • Leonard RCF, Adamson D, Bertelli G, McLinden M, Haiying N, Dunlop J, Mansi J, Coleman RE, Thomas G & Anderson R (2012) . Journal of Clinical Oncology, 30(15_suppl), 1094-1094.
  • Goss PE, Barrios CH, Bell R, Finkelstein DM, Iwata H, Martin M, Braun AH, Ke C, Maniar T & Coleman RE (2012) . Journal of Clinical Oncology, 30(15_suppl), TPS670-TPS670.
  • Smith MR, Saad F, Coleman R, Ye Z & Goessl C (2012) . LANCET, 379(9828), E50-E51.
  • Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Garcia A & Perez E (2012) . Annals of Oncology, 23, ii43-ii43.
  • Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee K-A, Coleman RE & Smith MR (2012) . ONCOLOGIST, 17, 645-652.
  • Lewington V, Boehmer S, Franzén L, Klijer R, Mellado B, Coleman R, Cross A, Biggin C & Parker C (2012) . Radiotherapy and Oncology, 103, S147-S147.
  • Canney P, Coleman R, Morden J, Barrett-Lee P, Banerji J, Wardley A, Murray N, Laing R, Cameron D & Bliss J (2012) . European Journal of Cancer, 48, S102-S102.
  • Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R , van de Velde CJH et al (2012) . J Clin Oncol, 30(7), 709-717.
  • Coleman RE, Marshall H, Bell R & Investigators AZURE (2012) Breast-Cancer Adjuvant Therapy with Zoledronic Acid REPLY. NEW ENGLAND JOURNAL OF MEDICINE, 366(2), 189-189.
  • Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R , Tammela TL et al (2012) . LANCET, 379(9810), 39-46.
  • Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW & Lawrie TA (2012) . COCHRANE DATABASE OF SYSTEMATIC REVIEWS(12).
  • Lipton A, Cook R, Brown J, Coleman R, Body JJ & Smith M (2012) . Clinical Oncology.
  • Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A & Aapro MS (2012) . Cancer Treatment Reviews, 38(6), 798-806.
  • Coleman RE, Marshall H & Bell R (2012) The authors reply. New England Journal of Medicine, 366(2), 189.
  • Brown JE & Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature Reviews Clinical Oncology, 9(2), 110-118.
  • Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL & Smith IE (2012) . Clin Oncol (R Coll Radiol), 24(3), 169-176.
  • Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE & Holen I (2012) . Breast Cancer Res Treat, 133(2), 523-536.
  • Coleman RE (2011) . Nat Rev Clin Oncol, 9(2), 76-78.
  • Pivot X, Hackmann J, Manikhas A, Moore Y, Parikh R, Kothari D, Joshi A, Aktan G & Coleman R (2011) . Poster Session Abstracts.
  • Coleman R, De BR, Eidtmann H, Neven P, von MG, Martin N, Modi A & Bundred N (2011) . Poster Session Abstracts.
  • Coleman R, Woodward E, Turner L, Marshall H, Collinson M, Dodwell D, Davies C, Bell R, Cameron D & Brown J (2011) . Poster Session Abstracts.
  • de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A & Coleman R (2011) . CANCER RESEARCH, 71.
  • Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun A, Ke C, Maniar T, Braun S , Dansey R et al (2011) . Ongoing Clinical Trials Poster Session Abstracts.
  • Coleman R, Flamen P, Naume B, Jerusalem G, Garcia C, Piccart M, OBryan-Tear CG & Aksnes A-K (2011) . Poster Session Abstracts.
  • Matthews GA, Burkinshaw R, Davies C, Hiley V, Marshall HC & Coleman RE (2011) . Trials, 12(S1).
  • Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ , Ritchie D et al (2011) . N Engl J Med, 365(15), 1396-1405.
  • Borkowski T, Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L , Damiao R et al (2011) . European Urology Supplements, 10(9), 656-656.
  • Garcia A, Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ , Cocquyt V et al (2011) . Journal of Clinical Oncology, 29(27_suppl), 269-269.
  • Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P & Tidy J (2011) . GYNECOL ONCOL, 122(3), 595-599.
  • Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO , Wardley A et al (2011) . J CLIN ONCOL, 29(24), 3247-3254.
  • Hadji P, Gnant M, Aapro M, Lipton A & Coleman R (2011) . CRIT REV ONCOL HEMAT, 79(2), 175-188.
  • Din OS, Dodwell D, Winter MC, Mori S & Coleman RE (2011) . Clin Oncol (R Coll Radiol), 23(10), 674-680.
  • Wilson C & Coleman RE (2011) . Curr Opin Support Palliat Care, 5(3), 241-250.
  • Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO , Wardley A et al (2011) . J Clin Oncol, 29(24), 3247-3254.
  • Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P & Tidy J (2011) . Gynecol Oncol, 122(3), 595-599.
  • Walkington L, Webster J, Hancock BW, Everard J & Coleman RE (2011) . Br J Cancer, 104(11), 1665-1669.
  • Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun AH, Dansey RD & Coleman RE (2011) A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).. J Clin Oncol, 29(15_suppl), TPS152.
  • Awada A, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V , Sideras K et al (2011) Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).. J Clin Oncol, 29(15_suppl), 1034.
  • Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun AH, Dansey RD & Coleman RE (2011) . Journal of Clinical Oncology, 29(15_suppl), TPS152-TPS152.
  • Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V , Sideras K et al (2011) . Journal of Clinical Oncology, 29(15_suppl), 1034-1034.
  • Coleman R (2011) . Nat Rev Urol, 8(6), 296-298.
  • Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body J-J, Smith M , Lee K-A et al (2011) . Crit Rev Oncol Hematol, 80(3), 411-432.
  • Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R , Houston SJ et al (2011) . Breast Cancer Res Treat, 127(2), 429-438.
  • Coleman RE & McCloskey EV (2011) . Bone, 49(1), 71-76.
  • Oliver RTD, Mead GM, Rustin GJS, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P & Stenning SP (2011) . J Clin Oncol, 29(8), 957-962.
  • Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL & Smith IE (2011) UK Guidance Document: Treatment of Metastatic Breast Cancer. Clinical Oncology.
  • Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R , Tammela TL et al (2011) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet.
  • Luis IV & Coleman R (2011) Ovarian germ cell malignancy: a heterogeneous tumour requiring supra-regional management. EUR J GYNAECOL ONCOL, 32(4), 387-392.
  • Ring A, Reed M, Leonard R, Kunkler I, Muss H, Wildiers H, Fallowfield L, Jones A & Coleman R (2011) . British Journal of Cancer, 105(2), 189-193.
  • Ortmann O, Pagani O, Jones A, Maass N, Noss D, Rugo H, van de Velde C, Aapro M & Coleman R (2011) . Cancer Treatment Reviews, 37, 97-104.
  • Aapro MS & Coleman RE (2011) . The Breast, 21(1), 8-19.
  • Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB & Thompson AM (2011) Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews.
  • Lipton A, Costa L & Coleman RE (2011) . Breast Disease, 33(2), 59-69.
  • Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T & Lipton A (2011) . Annals of Oncology, 22(12), 2546-2555.
  • Costa L, Harper P, Coleman RE & Lipton A (2011) . Critical Reviews in Oncology/Hematology, 77(SUPPL.1).
  • Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E & Brown J (2011) . Expert Opin Drug Saf, 10(1), 133-145.
  • Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW & Coleman RE (2011) . Ann Oncol, 22(4), 857-862.
  • Coleman R (2011) . Ann N Y Acad Sci, 1218, 3-14.
  • Arden-Close E, Absolom K, Greenfield DM, Hancock BW, Coleman RE, Eiser C & Late Effects Group Sheffield (2011) . Psychooncology, 20(11), 1202-1210.
  • Coleman R, Cook R, Hirsh V, Major P & Lipton A (2011) . Cancer, 117(1), 11-23.
  • Walkington L & Coleman RE (2011) . Bone, 48(1), 80-87.
  • Brown HK, Ottewell PD, Coleman RE & Holen I (2011) . J Cell Mol Med, 15(3), 501-513.
  • Holen I & Coleman RE (2010) . Breast Cancer Res, 12(6), 214.
  • Martin M, Mackey J, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T , Hainsworth J et al (2010) . General Session Abstracts.
  • Awada A, Chan S, Jerusalem G, Huizing M, Coleman RE, Mehdi A, O'Reilly SM, Hamm JT, Patel T, Hannah AL , Masuoka LK et al (2010) . Poster Session Abstracts.
  • Lo C, Busch S, Lee AG, Searle G, Lamb R, Cramer A, Winter MC, Coleman RE, Dixon M, Bundred NJ & Landberg G (2010) . Poster Session Abstracts.
  • Guise TA, Brufsky A & Coleman RE (2010) . Current Medical Research and Opinion, 26(sup3), 3-20.
  • Guise TA, Brufsky A & Coleman RE (2010) Understanding and optimizing bone health in breast cancer. CURR MED RES OPIN, 26, 6-20.
  • Lo C, Busch S, Lee A, Searle G, Lamb R, Cramer A, Morris J, Winter M, Coleman R, Dixon JM , Bundred N et al (2010) . European Journal of Surgical Oncology (EJSO), 36(11), 1099-1100.
  • Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N & Coleman R (2010) . ANN ONCOL, 21(11), 2188-2194.
  • Noon E, Singh S, Cuzick J, Spector TD, Williams FMK, Frost ML, Howell A, Harvie M, Eastell R, Coleman RE , Fogelman I et al (2010) . OSTEOPOROSIS INT, 21(11), 1871-1880.
  • Lee A, Lamb R, Gregson H, Cramer A, Morris J, Renshaw L, Winter M, Coleman RE, Dixon JMJ, Landberg G & Bundred NJ (2010) . European Journal of Cancer Supplements, 8(6), 17-17.
  • Woodward EJ & Coleman RE (2010) . Curr Pharm Des, 16(27), 2998-3006.
  • Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J , Jones AL et al (2010) . BREAST CANCER RES TR, 122(3), 787-794.
  • Price JM, Hancock BW, Tidy J, Everard J & Coleman RE (2010) Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia.. J Reprod Med, 55(7-8), 301-304.
  • Walsh JS, Eastell R, Coleman RE, Snowden JA, Shalet SM, Ross RJ & Greenfield DM (2010) . Bone, 47, S189-S190.
  • Neville-Webbe HL, Gnant M & Coleman RE (2010) . Semin Oncol, 37 Suppl 1, S53-S65.
  • Amir E, Clemons M, Freedman OC, Miller N, Coleman RE, Purdie C, Jordan L, Quinlan P & Thompson AM (2010) . Journal of Clinical Oncology, 28(15_suppl), 1007-1007.
  • Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals JJ, Tres A, Coleman RE, Reise J, Cooper D & Hupperets P (2010) . JOURNAL OF CLINICAL ONCOLOGY, 28(15).
  • Amir E, Clemons M, Freedman OC, Miller N, Coleman RE, Purdie C, Jordan L, Quinian P & Thompson AM (2010) Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospectice studies.. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
  • Leonard RC, Adamson D, Anderson R, Ballinger R, Bertelli G, Coleman RE, Fallowfield L, McLinden M, Mansi J & Thomas G (2010) . JOURNAL OF CLINICAL ONCOLOGY, 28(15).
  • Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P , Holen I et al (2010) . Cancer Treat Rev, 36(8), 615-620.
  • Neville-Webbe HL & Coleman RE (2010) . Eur J Cancer, 46(7), 1211-1222.
  • Coulson SG, Kumar VS, Manifold IM, Hatton MQ, Ramakrishnan S, Dunn KS, Purohit OP, Bridgewater C & Coleman RE (2010) . Clin Oncol (R Coll Radiol), 22(4), 289-293.
  • Terpos E, Berenson J, Cook RJ, Lipton A & Coleman RE (2010) . LEUKEMIA, 24(5), 1043-1049.
  • Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ & Holen I (2010) . J Vasc Res, 47(6), 481-493.
  • Coleman R & MacCallum P (2010) . Br J Cancer, 102 Suppl 1, S17-S23.
  • Din OS, Dodwell D, Wakefield RJ & Coleman RE (2010) . Breast Cancer Res Treat, 120(3), 525-538.
  • Bhattacharya A, Watts NB, Davis K, Kotowski S, Shukla R, Dwivedi AK & Coleman R (2010) . Journal of Clinical Densitometry, 13(2), 228-236.
  • Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D , Burkinshaw R et al (2010) . Br J Cancer, 102(7), 1099-1105.
  • Neville-Webbe HL, Coleman RE & Holen I (2010) . Br J Cancer, 102(6), 1010-1017.
  • Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Snowden JA, Shalet SM, DeRogatis LR & Ross RJM (2010) . Cancer, 116(6), 1592-1601.
  • Lester JE, Brown JE, Hannon RA, Ellis SP, Horsman JM, Purohit OP & Coleman RE (2010) . Bone, 46(3), 801-805.
  • Holen I & Coleman RE (2010) . Curr Pharm Des, 16(11), 1262-1271.
  • Dranitsaris G, Coleman R & Gradishar W (2010) . BREAST CANCER RES TR, 119(3), 717-724.
  • Winter MC, Neville-Webbe HL & Coleman RE (2010) , 275-297.
  • Brown JE & Coleman RE (2010) . Expert Opinion on Medical Diagnostics, 4(2), 125-138.
  • Brown JE, Cook RJ, Lipton A, Costa L & Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 123, 767-779.
  • Coleman RE & Walsh JS (2010) . NAT REV ENDOCRINOL, 6(1), 10-12.
  • Murray LJ, Ramakrishnan S, O'Toole L, Manifold IH, Purohit OP & Coleman RE (2010) . Breast, 19(5), 339-344.
  • Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE & Holen I (2010) . Int J Cancer, 126(2), 522-532.
  • Coleman R, Bundred N, De Boer R, Llombarto A, Campbell I, Neven P, Barrios C, Dias R, Miller J & Brufsky A (2009) . Cancer Research, 69(24_Supplement), 4082-4082.
  • Winter MC & Coleman RE (2009) . Curr Opin Oncol, 21(6), 499-506.
  • Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE & Holen I (2009) . Mol Cancer Ther, 8(10), 2821-2832.
  • Coleman R & Gnant M (2009) . Curr Opin Support Palliat Care, 3(3), 213-218.
  • Absolom K, Eiser C, Michel G, Walters SJ, Hancock BW, Coleman RE, Snowden JA & Greenfield DM (2009) . Br J Cancer, 101(4), 561-567.
  • Greenfield DM, Absolom K, Eiser C, Walters SJ, Michel G, Hancock BW, Snowden JA & Coleman RE (2009) . Br J Cancer, 101(4), 568-574.
  • Major PP, Cook RJ, Lipton A, Smith MR, Terpos E & Coleman RE (2009) . BMC Cancer, 9(1).
  • Coleman R (2009) Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial COMMENT. J UROLOGY, 182(2), 515-516.
  • Dodwell D, Thorpe H & Coleman R (2009) Refining systemic therapy for early breast cancer: difficulties with subtraction. LANCET ONCOL, 10(8), 738-739.
  • Coleman RE (2009) . Eur J Cancer, 45(11), 1909-1915.
  • Aboumarzouk OM, Coleman R, Goepel JR & Shorthouse AJ (2009) . Case Reports, 2009(jun21 1), bcr0420091770-bcr0420091770.
  • Coleman RE (2009) . CLIN ONCOL-UK, 21(5), 365-367.
  • El-Helw LM, Coleman RE, Everard JE, Tidy JA, Horsman JM, Elkhenini HF & Hancock BW (2009) . Gynecol Oncol, 113(3), 306-311.
  • Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC).. J Clin Oncol, 27(15_suppl), e16016.
  • Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer.. J Clin Oncol, 27(15_suppl), e11625.
  • Dranitsaris G, Coleman R & Gradishar W (2009) Nab-paclitaxel weekly or q3w compared to docetaxel q3w as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial.. J Clin Oncol, 27(15_suppl), 6592.
  • Coleman RE, Colwell BB, Freeman JV, Holmes KR & Reed MW (2009) Preparing patients for discharge from routine hospital follow-up for breast cancer. PSYCHO-ONCOL, 18(3), 316-317.
  • Coleman RE (2009) . Nat Clin Pract Endocrinol Metab, 5(2), 72-73.
  • Ottewell PD, Lefley DV, Coleman RE & Holen I (2009) . Poster Session Abstracts.
  • Noon E, Singh S, Cuzick J, Spector TD, Williams FMK, Frost ML, Howell A, Harvie M, Eastell R, Coleman RE , Fogelman I et al (2009) Significant differences in UK and US female bone density reference ranges. Osteoporosis International, 21(11), 1871-1880.
  • Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R , Earl H et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. LANCET, 373(9676), 1681-1692.
  • Biganzoli L, Bonnefoi H, Cardoso F, Coleman R & Thurlimann B (2009) . BREAST CARE, 4(4), 268-271.
  • Saad F, Cook R, Coleman R & Lipton A (2008) . Urology, 72(5), S39-S39.
  • Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R & Major P (2008) . Cancer Treat Rev, 34(7), 629-639.
  • Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, Coleman R, Hancock B, Snowden J, Greenfield D & Late Effects Group Sheffield (2008) . Hum Reprod, 23(11), 2506-2512.
  • Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS , Coleman RE et al (2008) . CLIN CANCER RES, 14(20), 6690-6696.
  • Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body J-J, Boyce BF, Calvi LM, Hadji P, McCloskey EV , Saad F et al (2008) . Clin Cancer Res, 14(20), 6387-6395.
  • Fallowfield L, Jenkins V & Coleman R (2008) . BREAST, 17(5), 459-463.
  • Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) . Clin Cancer Res, 14(19), 6336-6342.
  • Zekri JM, El-Helw LM, Purohit OP, Hatton MQ & Coleman RE (2008) . Clin Oncol (R Coll Radiol), 20(7), 513-516.
  • Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE & Holen I (2008) . J Natl Cancer Inst, 100(16), 1167-1178.
  • Wardley AM, Hiller L, Howard HC, Dunn JA, Bowman A, Coleman RE, Fernando IN, Ritchie DM, Earl HM, Poole CJ & tAnGo Trial Collaborators (2008) . BRIT J CANCER, 99(4), 597-603.
  • Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A & Tubiana-Hulin M (2008) . ANN ONCOL, 19(8), 1407-1416.
  • Winter MC, Holen I & Coleman RE (2008) . Cancer Treat Rev, 34(5), 453-475.
  • Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P & Holen I (2008) . Clin Cancer Res, 14(14), 4658-4666.
  • Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE & Coleman RE (2008) . CANCER, 113(1), 193-201.
  • Coleman RE (2008) . Br J Cancer, 98(11), 1736-1740.
  • Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM, Kennedy MJ, Coleman RE, Leonard RC & Earl HM (2008) . Journal of Clinical Oncology, 26(15_suppl), 506-506.
  • Brown JE, Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR & Coleman RE (2008) Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP.. J Clin Oncol, 26(15_suppl), 19003.
  • Coleman RE & ATAC Trialists’ Group (2008) Long-term effects of anastrozole on bone mineral density: Seven-year results from the ATAC trial.. J Clin Oncol, 26(15_suppl), 587.
  • Evans TR, Yellowlees A, Devine I, Earl HM, Cameron DA, Hutcheon AW, Coleman RE, Crown JP, Leonard RC & Mansi JL (2008) 5-year outcome for women randomised in a phase III trial comparing doxorubicin (A) and cyclophosphamide (C) with doxorubicin and docetaxel (D) as primary medical therapy of breast cancer: An Anglo-Celtic Cooperative Oncology Group Study.. J Clin Oncol, 26(15_suppl), 540.
  • Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study.. J Clin Oncol, 26(15_suppl), 554.
  • Dranitsaris G, Lidgren M, Lundkvist J & Coleman RE (2008) Nab-paclitaxel or docetaxel as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): a cost utility analysis in five European countries.. J Clin Oncol, 26(15_suppl), 6571.
  • Cook RJ, Hirsh V, Major PP, Saad F, Dias R, Lipton A & Coleman RE (2008) Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): Survival in patients with high bone turnover.. J Clin Oncol, 26(15_suppl), 20562.
  • Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N & Hadji P (2008) . Cancer Treat Rev, 34(3), 275-282.
  • Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J , Basaran G et al (2008) . BREAST, 17(2), 180-185.
  • Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J , Hadji P et al (2008) . ANN ONCOL, 19(3), 420-432.
  • Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL & Coleman RE (2008) . CANCER, 112(5), 1001-1010.
  • Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE & Coleman RE (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J THORAC ONCOL, 3(3), 228-236.
  • Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW & Clack G (2008) . J Clin Oncol, 26(7), 1051-1057.
  • Lester J, Dodwell D, Purohit O, Gutcher S, Ellis S, Thorpe R, Horsman J, Brown J, Hannon R & Coleman R (2008) . Cancer Treatment Reviews, 34, 51-52.
  • Coleman R (2008) . Cancer Treatment Reviews, 34, 47-48.
  • Press MF, Finn RS, Cameron D, Leo AD, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y , Danenberg K et al (2008) . Clinical Cancer Research, 14(23), 7861-7870.
  • Coleman RE (2008) . CANCER TREAT REV, 34, S1-S1.
  • Coleman RE, Body J-J, Gralow JR & Lipton A (2008) . Cancer Treat Rev, 34 Suppl 1, S31-S42.
  • Coleman R (2008) . BMJ, 337, a2555.
  • Eastell R, Adams JE, Clack G, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann M & Coleman R (2008) Effect of stopping anastrozole on bone mineral density: Seven-year results from the ATAC trial. CALCIFIED TISSUE INT, 82, S84-S84.
  • Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P & Coleman RE (2008) . Cancer Treat Rev, 34 Suppl 1, S3-18.
  • Bhattacharya A, Watts NB, Gordon J, Shukla R, Waters T, Bartels S & Coleman R (2008) . Journal of Agromedicine, 12(4), 27-38.
  • Coleman R (2007) . Breast, 16 Suppl 3, S21-S27.
  • Coleman RE (2007) . Semin Oncol, 34(6 Suppl 4), S11-S16.
  • Coleman RE (2007) . Seminars in Oncology, 34(6), S1-S3.
  • Daley AJ, Crank H, Mutrie N, Saxton JM & Coleman R (2007) . EUR J ONCOL NURS, 11(5), 392-399.
  • Woodward JKL, Holen I, Coleman RE & Buttle DJ (2007) . Bone, 41(6), 912-927.
  • Berenson J, Cook R, Lipton A, Coleman R & Terpos E (2007) . Blood, 110(11), 1499-1499.
  • Terpos E, Cook R, Coleman R, Lipton A & Berenson J (2007) . Blood, 110(11), 1482-1482.
  • Coleman RE (2007) The benefits and costs of bisphosphonates.. J Support Oncol, 5(10), 483-484.
  • Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R & Coleman RE (2007) . Calcif Tissue Int, 81(5), 341-351.
  • Saad F, Lipton A, Cook R, Chen YM, Smith M & Coleman R (2007) . CANCER, 110(8), 1860-1867.
  • Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O-P, McCloskey E & Coleman RE (2007) . Clin Cancer Res, 13(18 Pt 1), 5406-5410.
  • Saad F, Lipton A & Coleman R (2007) . Urology, 70(3), 84-85.
  • Donnelly P, Hiller L, Bathers S, Bowden S & Coleman R (2007) . ANN ONCOL, 18(9), 1467-1476.
  • Daley AJ, Crank H, Mutrie N, Saxton JM & Coleman R (2007) . CONTEMP CLIN TRIALS, 28(5), 603-613.
  • Lipton A, Cook RJ, Major P, Smith MR & Coleman RE (2007) . ONCOLOGIST, 12(9), 1035-1043.
  • Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Eastell R, Davies HA, Snowden JA, Derogatis L, Shalet SM & Ross RJM (2007) . J Clin Endocrinol Metab, 92(9), 3476-3482.
  • Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ & Saad F (2007) . UROLOGY, 70(2), 315-319.
  • Coleman R (2007) . Clin Breast Cancer, 7 Suppl 1, S29-S35.
  • Verrill MW, Lee J, Cameron DA, Agrawal R, Coleman RE, McAdam K, Wardley A, Bowman A, Ferrigan L & Yellowlees A (2007) . Journal of Clinical Oncology, 25(18_suppl), LBA1005-LBA1005.
  • Lipton A, Cook R, Coleman RE, Major P, Terpos E, Body J, Smith MR, Brown J & Garnero P (2007) . Journal of Clinical Oncology, 25(18_suppl), 9013-9013.
  • Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D & Coleman RE (2007) . Journal of Clinical Oncology, 25(18_suppl), 553-553.
  • Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R & Roalfe A (2007) . J CLIN ONCOL, 25(13), 1713-1721.
  • Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Dong M, Schenk N, Lacerna L & Perez E (2007) . The Breast, 16, S57-S57.
  • Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R & Aapro M (2007) . EUR J CANCER, 43(5), 852-858.
  • Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E & Berenson JR (2007) Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. CLIN LYMPHOMA MYELOM, 7(5), 346-353.
  • Eiser C, Absolom K, Greenfield D, Snowden J, Coleman R, Hancock B, Davies H & Late Effects Group, Sheffield (LEGS) (2007) . J Cancer Surviv, 1(1), 75-86.
  • Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJH, Delozier T, Alvarez I , Del Mastro L et al (2007) . LANCET, 369(9561), 559-570.
  • Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E , Bliss JM et al (2007) . Lancet Oncol, 8(2), 119-127.
  • Smith I, Procter M, D Gelber R, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J , Kaufmann M et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. LANCET, 369(9555), 29-36.
  • Biganzoli L, Coleman R, Minisini A, Hamilton A, Aapro M, Therasse P, Mottino G, Bogaerts J & Piccart M (2007) . CRIT REV ONCOL HEMAT, 61(1), 84-89.
  • Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P & Paridaens R (2007) . EUR J CANCER, 43(2), 331-340.
  • Martin J, Coleman R & Mundy G (2007) . Expert Review of Anticancer Therapy, 7(4), 461-464.
  • Hodgkinson E, Neville-Webbe HL & Coleman RE (2006) . Clin Oncol (R Coll Radiol), 18(9), 710-718.
  • Brown JE, Ellis SP, Silcocks P, Blumsohn A, Gutcher SA, Radstone C, Hancock BW, Hatton MQ & Coleman RE (2006) . Clin Cancer Res, 12(21), 6480-6486.
  • Coleman RE (2006) . Clin Cancer Res, 12(20 Pt 2), 6243s-6249s.
  • El-Helw LM, Naik JD, Chester JD, Joffe JK, Selby PJ & Coleman RE (2006) . BJU Int, 98(3), 519-525.
  • Coleman RE & ATAC Trialists’ Group (2006) Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.. J Clin Oncol, 24(18_suppl), 511.
  • Shirina N, Coleman RE & Chen YM (2006) Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.. J Clin Oncol, 24(18_suppl), 8529.
  • Saad F, Coleman RE, Cook R, Smith MR, Brown JE, Hei JY & Chen YM (2006) . Journal of Clinical Oncology, 24(18_suppl), 4555-4555.
  • Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, Manifold I, Kunkler I, Purohit I & Cameron D (2006) . BREAST, 15(3), 430-436.
  • Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F & Smith MR (2006) . CLIN CANCER RES, 12(11), 3361-3367.
  • Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C & Piccart M (2006) . Eur J Cancer, 42(7), 882-887.
  • Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A , Caraglia M et al (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. ONCOL REP, 15(5), 1351-1357.
  • Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MWR, Coleman RE & Holen I (2006) . Int J Cancer, 118(8), 1901-1908.
  • Jiwa M, Thompson J, Coleman R & Reed M (2006) . CURR MED RES OPIN, 22(4), 625-630.
  • Bundred N, Campbell , Coleman R, DeBoer R, Edidtmann H, Frassolati A, Llombart A, Monnier A, Neven P & Dias R (2006) . European Journal of Cancer Supplements, 4(2), 48-48.
  • Chong G, Bhatnagar A, Cunningham D, Cosgriff TM, Harper PG, Steward W, Bridgewater J, Moore M, Cassidy J, Coleman R , Coxon F et al (2006) . ANN ONCOL, 17(3), 437-442.
  • Ottewell PD, Coleman RE & Holen I (2006) . Breast Cancer Res Treat, 96(2), 101-113.
  • Greenfield DM, Wright J, Brown JE, Hancock BW, Davies HA, O'Toole L, Eiser C, Coleman RE & Ross RJ (2006) . Br J Cancer, 94(4), 469-472.
  • Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR & ATAC Trialists' Grp (2006) . HUM REPROD, 21(2), 545-553.
  • Vasey PA, Atkinson R, Osborne R, Parkin D, Symonds R, Paul J, Lewsley L, Coleman R, Reed NS, Kaye S & Rustin GJS (2006) . BRIT J CANCER, 94(1), 62-68.
  • Lester JE, Dodwell D, Horsman JM, Mori S & Coleman RE (2006) . Br J Cancer, 94(1), 30-35.
  • Coleman RE, Mccloskey EV, Guest JF, Ashford RU & Kanis JA (2006) , 415-426.
  • Coleman RE, Ashford RU, Mccloskey EV & Kanis JA (2006) , 399-414.
  • Reed NS, Poole CJ, Coleman R, Parkin D, Graham JD, Kaye SB, Ostrowski J, Duncan I, Paul J & Hay A (2006) . EUR J CANCER, 42(2), 179-185.
  • Costa L, Lipton A & Coleman RE (2006) . Supportive Cancer Therapy, 3(3), 143-153.
  • Coleman RE (2006) . Cancer Treat Rev, 32 Suppl 1, 1-2.
  • Burkinshaw R & Coleman R (2006) . Womens Health (Lond), 2(1), 115-126.
  • Coleman RE (2006) . Cancer Treat Rev, 32 Suppl 1, 27-28.
  • Saxton JM, Daley A, Woodroofe N, Coleman R, Powers H, Mutrie N, Siddall V & Crank H (2006) . BMC Cancer, 6, 35.
  • Michailidou M, Neville-Webbe HL, Woodward JK, Lefley DV, Brown NJ, Coleman RE & Holen I (2006) The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro. Haematologica Reports, 2(3), 48-49.
  • Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE & Holen I (2006) . J Clin Pathol, 59(1), 56-63.
  • Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2006) . Tumour Biol, 27(2), 92-103.
  • Coleman RE (2005) . SUPPORT CARE CANCER, 13(12), 959-960.
  • Thompson J, Jiwa M, Coleman R & Reed M (2005) Breast cancer aftercare; Psychosocial support in primary care (BCAPS). PSYCHO-ONCOL, 14(12), 1091-1091.
  • Hassadia A, Gillespie A, Tidy J, Everard R G N J, Wells M, Coleman R & Hancock B (2005) . Gynecol Oncol, 99(3), 603-607.
  • El-Helw L & Coleman RE (2005) . Breast, 14(5), 368-374.
  • Lipton A, Hei Y, Coleman R, Major P, Smith M & Cook R (2005) Breast cancer patients with persistently increased bone resorption. EJC SUPPL, 3(2), 121-121.
  • Lichinitser M, Coleman RE, Tjulandin SA, Bergstrom B & Body JJ (2005) Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparison of bone turnover markers. EJC SUPPL, 3(2), 113-113.
  • Body JJ, Lichinitser M, Tjulandin SA, Coleman RE & Bergstrom B (2005) Safety comparison of oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: Phase III data. EJC SUPPL, 3(2), 114-114.
  • Woodward JKL, Neville-Webbe HL, Coleman RE & Holen I (2005) . Anticancer Drugs, 16(8), 845-854.
  • Lester J & Coleman R (2005) . Br J Cancer, 93 Suppl 1, S16-S22.
  • Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J & Cook R (2005) . J Clin Oncol, 23(22), 4925-4935.
  • Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE & Eaton CL (2005) . Breast Cancer Res Treat, 92(3), 207-215.
  • Oliver RTD, Mason MD, Mead GM, von der Maase H, Rustin GJS, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R , Kirk SJ et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. LANCET, 366(9482), 293-300.
  • Serin D, Verrill M, Jones A, Delozier T, Coleman R, Kreuser ED, Mross K, Longerey B & Brandely M (2005) . BRIT J CANCER, 92(11), 1989-1996.
  • Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E , Guevin R et al (2005) Adjuvant docetaxel for node-positive breast cancer. NEW ENGL J MED, 352(22), 2302-2313.
  • Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit O-P, Hancock B & Coleman R (2005) . Journal of Clinical Oncology, 23(16_suppl), 8023-8023.
  • Lipton A, Hei Y, Coleman R, Major P & Cook R (2005) Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome.. J Clin Oncol, 23(16_suppl), 532.
  • El-Helw L & Coleman RE (2005) . Cancer Treat Rev, 31(3), 197-209.
  • Coleman RE (2005) . Ann Oncol, 16(5), 687-695.
  • Lester J, Dodwell D, McCloskey E & Coleman R (2005) . Cancer Treat Rev, 31(2), 115-142.
  • Lester J & Coleman R (2005) . J Br Menopause Soc, 11(1), 12-17.
  • Zheng M, Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Apffelstaedt J, Hussein M, Hei Y & Coleman R (2005) . The Breast, 14, S44-S44.
  • Reed SD, Radeva JI, Glendenning GA, Coleman RE & Schulman KA (2005) . AM J CLIN ONCOL-CANC, 28(1), 8-16.
  • Lester J & Coleman R (2005) . Breast Cancer Online, 8(1).
  • Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE & Holen I (2005) . Int J Cancer, 113(3), 364-371.
  • Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K-A, Zheng M, Hei Y-J & Coleman RE (2005) . J Natl Cancer Inst, 97(1), 59-69.
  • Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Içli F, Pegram M , Piccart M et al (2005) . Clinical Breast Cancer, 6(5), 412-420.
  • Woodward JKL, Coleman RE & Holen I (2005) . Anticancer Drugs, 16(1), 11-19.
  • Coleman RE (2004) . Breast, 13 Suppl 1, S19-S28.
  • Daley AJ, Mutrie N, Crank H, Coleman R & Saxton J (2004) . HEALTH EDUC RES, 19(6), 686-697.
  • Pezeshki M, Hancock BW, Silcocks P, Everard JE, Coleman J, Gillespie AM, Tidy J & Coleman RE (2004) . Gynecol Oncol, 95(3), 423-429.
  • Gennery AR, Slatter MA, Bhattacharya A, Barge D, Haigh S, O'Driscoll M, Coleman R, Abinun M, Flood TJ, Cant AJ & Jeggo PA (2004) . Clinical Immunology, 113(2), 214-219.
  • Gilbey AM, Burnett D, Coleman RE & Holen I (2004) . J CLIN PATHOL, 57(9), 903-911.
  • Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, Poole C, Crawford M, Hancock B, Selby PJ & Perren TJ (2004) . BRIT J CANCER, 91(4), 621-626.
  • Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE & Holen I (2004) . Breast Cancer Res Treat, 86(3), 269-279.
  • Leonard RCF, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T , Verrill M et al (2004) . JNCI Journal of the National Cancer Institute, 96(14), 1076-1083.
  • Coleman R (2004) . Journal of Clinical Oncology, 22(14_suppl), 767-767.
  • Coleman R (2004) . Journal of Clinical Oncology, 22(14_suppl), 767-767.
  • Poole CJ, Howard HC, Hiller L, Dunn JA, Wardley AM, Bowman A, Coleman RE, Fernando IN, Ritchie DM & Earl HM (2004) . Journal of Clinical Oncology, 22(14_suppl), 821-821.
  • Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Crown J, Leonard RC & Mansi JL (2004) . Journal of Clinical Oncology, 22(14_suppl), 521-521.
  • Poole CJ, Howard HC, Hiller L, Dunn JA, Wardley AM, Bowman A, Coleman RE, Fernando IN, Ritchie DM & Earl HM (2004) . Journal of Clinical Oncology, 22(14_suppl), 821-821.
  • Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Crown J, Leonard RC & Mansi JL (2004) . Journal of Clinical Oncology, 22(14_suppl), 521-521.
  • Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) . Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
  • Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) . Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
  • Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P & Piccart M (2004) . J CLIN ONCOL, 22(13), 2576-2586.
  • Brown JE & Coleman RE (2004) . American Journal of Cancer, 3(4), 265-265.
  • Warren (2004) . The Women's Oncology Review, 4(2), 127-128.
  • Brown JE, Neville-Webbe H & Coleman RE (2004) . Endocr Relat Cancer, 11(2), 207-224.
  • Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C , Fargeot P et al (2004) . EUR J CANCER, 40(7), 1021-1030.
  • Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P & Quadrament 424Sm10-11 Study Grp (2004) . UROLOGY, 63(5), 940-945.
  • Coleman RE (2004) Hormone- and chemotherapy-induced bone loss in breast cancer.. Oncology (Williston Park), 18(5 Suppl 3), 16-20.
  • Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP , Houghton J et al (2004) . Journal of Clinical Oncology, 22(8), 1524-1526.
  • Gumbrell LA, Evans TRJ, Coleman RE, Smith IE, Twelves CJ, Soukop M, Rea DW, Earl HM, Howell A, Jones A , Canney P et al (2004) . Cancer Chemotherapy and Pharmacology, 53(4), 341-348.
  • Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O , Coates AS et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. NEW ENGL J MED, 350(11), 1081-1092.
  • Paridaens R, Dyczka J, Rutgers EJT, Coleman R, Cufer T, Jassem J, Nortier JWR, Morales L, Mattiacci MR & Therasse P (2004) . European Journal of Cancer Supplements, 2(3), 70-70.
  • Coleman R (2004) . European Journal of Cancer Supplements, 2(3), 32-33.
  • Serin D, Verrill M, Jones A, Delozier T, Coleman R, Longerey B & Lafaye de Micheaux S (2004) . European Journal of Cancer Supplements, 2(3), 130-131.
  • Bhala N, Coleman JM, Radstone CR, Horsman JM, George J, Hancock BW, Hatton MQ & Coleman RE (2004) . Clin Oncol (R Coll Radiol), 16(1), 40-47.
  • Coleman RE (2004) . Oncologist, 9 Suppl 4, 14-27.
  • Clemons M, Coleman RE & Verma S (2004) . Cancer Treatment Reviews, 30(4), 325-332.
  • Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL & Coleman RE (2004) . CANCER, 100(1), 36-43.
  • Galasko CSB (2004) . American Journal of Cancer, 3(4), 265-265.
  • Semple SE, Dick F & Cherrie JW (2004) . Scandinavian Journal of Work, Environment & Health, 30(3), 241-248.
  • Ralston SH, Coleman R, Fraser WD, Gallagher SJ, Hosking DJ, Iqbal JS, McCloskey E & Sampson D (2003) . Calcified Tissue International, 74(1), 1-11.
  • Khan F, Everard J, Ahmed S, Coleman RE, Aitken M & Hancock BW (2003) . British Journal of Cancer, 89(12), 2197-2201.
  • Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP & Coleman RE (2003) . Br J Cancer, 89(11), 2031-2037.
  • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ , Chen BL et al (2003) . CANCER, 98(8), 1735-1744.
  • Clamp AR, Blackhall FH, Vasey P, Soukop M, Coleman R, Halbert G, Robson L & Jayson GC (2003) . British Journal of Cancer, 89(7), 1152-1154.
  • Brown JE, Hatton MQ, Melchers R, Goldstraw P & Coleman RE (2003) . Clin Oncol (R Coll Radiol), 15(7), 371-377.
  • Brown JE & Coleman RE (2003) . American Journal of Cancer, 2(4), 269-281.
  • Coleman R (2003) . Clinical Oncology, 15(6), 369-369.
  • Verrill M, Serin D, Jones A, Delozier T & Coleman R (2003) . European Journal of Cancer Supplements, 1(5), S138-S139.
  • Neville-Webbe HL & Coleman RE (2003) . Palliat Med, 17(6), 539-553.
  • Bukowski R, Rosen LS, Gordon D, Tchekmedyian S, Hirsh V, Yanagihara R & Coleman RE (2003) . Lung Cancer, 41, S262-S263.
  • Eaton CL & Coleman RE (2003) . Cancer Treat Rev, 29(3), 189-198.
  • Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML, Eten CB & Finkler NJ (2003) . CANCER IMMUNOL IMMUN, 52(4), 243-248.
  • Rosen L, Coleman R, Gordon D, Major P, Kaminski M, Apffelstaedt J, Howell A, Chen BL & Seaman J (2003) . The Breast, 12, S42-S43.
  • Djulbegovic B, Coleman RE, Stahel RA, Singh D & Lyman G (2003) . CANCER TREAT REV, 29(1), 45-50.
  • Coleman RE (2003) . Cancer, 97(3 Suppl), 880-886.
  • Croucher P, Jagdev S & Coleman R (2003) . The Breast, 12, S30-S36.
  • Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR , Zani V et al (2003) . Annals of Oncology, 14(1), 29-35.
  • Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P & Piccart MJ (2003) . European Journal of Cancer, 39(17), 2439-2449.
  • Coleman RE (2002) . Am J Clin Oncol, 25(6 Suppl 1), S32-S38.
  • Coleman RE (2002) . Am J Clin Oncol, 25(6 Suppl 1), S25-S31.
  • Coleman RE (2002) . Semin Oncol, 29(6 Suppl 21), 43-49.
  • Neville-Webbe HL, Holen I & Coleman RE (2002) . Cancer Treat Rev, 28(6), 305-319.
  • Brown JE & Coleman RE (2002) . Breast, 11(5), 375-385.
  • Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R , Lohrisch C et al (2002) . Journal of Clinical Oncology, 20(14), 3114-3121.
  • Coleman RE (2002) . Cancer, 94(10), 2521-2533.
  • Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I , Bruning P et al (2002) . Annals of Oncology, 13(6), 910-918.
  • Brown JE & Coleman RE (2002) . Breast Cancer Res, 4(1), 24-29.
  • Ashford RU, McCloskey EV, Purohit OP, Ingram CE, Grimer RJ & Coleman RE (2002) . Sarcoma, 6(4), 131-133.
  • Jagdev SP, Purohit P, Heatley S, Herling C & Coleman RE (2001) . Ann Oncol, 12(10), 1433-1438.
  • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ , Seaman JJ et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. CANCER J, 7(5), 377-387.
  • LIPTON A (2001) . Seminars in Oncology, 28, 1-1.
  • Coleman RE (2001) . Semin Oncol, 28(4 Suppl 11), 35-41.
  • Lipton A, Coleman RE, Diel IJ & Mundy G (2001) Update on the role of bisphosphonates in metastatic breast cancer - Introduction. SEMIN ONCOL, 28(4), 1-1.
  • Zekri J, Ahmed N, Coleman RE & Hancock BW (2001) . Int J Oncol, 19(2), 379-382.
  • Miles DW, Smith IE, Coleman RE, Calvert AH & Lind MJ (2001) A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. EUR J CANCER, 37(11), 1366-1371.
  • Coleman RE (2001) . CANCER TREAT REV, 27(3), 133-135.
  • Jagdev SP, Coleman RE, Shipman CM, Rostami-H A & Croucher PI (2001) . Br J Cancer, 84(8), 1126-1134.
  • Coleman R, Apffelstaedt J, Gordon D, Major P, Mackey J, Howell A, Theriault R, Yambros Y, Chen B & Reitsma D (2001) . European Journal of Cancer, 37, S152-S152.
  • Jagdev SP, Croucher PI & Coleman RE (2001) . European Journal of Cancer, 37, S129-S129.
  • Coleman RE & Seaman JJ (2001) . Semin Oncol, 28(2 Suppl 6), 11-16.
  • Major PP & Coleman RE (2001) Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program. SEMIN ONCOL, 28(2), 17-24.
  • Berenson JR, Rosen LS, Howell A, Parter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A & Seaman JJ (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases - A double-blind, randomized dose-response study. CANCER, 91(7), 1191-1200.
  • Gore M, ten Bokkel Huinink W, Carmichael J, Gordon A, Davidson N, Coleman R, Spaczynski M, Héron J-F, Bolis G, Malmström H , Malfetano J et al (2001) . Journal of Clinical Oncology, 19(7), 1893-1900.
  • Cunningham D & Coleman R (2001) . Cancer Treatment Reviews, 27(4), 211-220.
  • Coleman RE (2001) . Cancer Treat Rev, 27(3), 165-176.
  • Lorigan PC, Sharma S, Bright N, Coleman RE & Hancock BW (2000) . Gynecol Oncol, 78(3 Pt 1), 288-292.
  • Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE & Hancock BW (2000) . Gynecol Oncol, 78(3 Pt 1), 309-312.
  • Coleman RE (2000) . Cancer, 88(12 Suppl), 3059-3064.
  • Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M & Coleman RE (2000) . Ann Oncol, 11(6), 735-741.
  • Hamilton A, Roy J-A, Beex L, Piccart M, Mauriac L, Coleman R, Paridaens R, Boes GH, van Vreckem A, Palmer P & Klijn J (2000) . Breast Cancer Research and Treatment, 60(2), 181-188.
  • Coleman RE, Howell A, Eggleton SP, Maling SJ & Miles DW (2000) . Ann Oncol, 11(5), 541-546.
  • Dobson LS, Lorigan PC, Coleman RE & Hancock BW (2000) . Br J Cancer, 82(9), 1547-1552.
  • Coleman RE, Howell A, Eggleton SPH, Maling SJ, Miles DW & UK Study Grp (2000) Phase II study of docetaxel in patients with liver metastases from breast cancer. ANN ONCOL, 11(5), 541-546.
  • El Helw LM, Lorigan PC, Robinson MH, Coleman RE & Hancock BW (2000) . Int J Oncol, 16(4), 777-782.
  • Gillespie AM, Liyim D, Goepel JR, Coleman RE & Hancock BW (2000) . Br J Cancer, 82(6), 1186-1190.
  • Paridaens R, Biganzoli L, Bruning P, Klijn JGM, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R , Awada A et al (2000) . Journal of Clinical Oncology, 18(4), 724-724.
  • Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE & Delmas PD (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. BRIT J CANCER, 82(4), 858-864.
  • Atkinson R, Vasey PA, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J , Reed NS et al (2000) . International Journal of Gynecology & Obstetrics, 70, D72-D72.
  • Coleman RE (2000) . Oncologist, 5(6), 463-470.
  • Coleman RE (2000) . Ann Oncol, 11 Suppl 3, 179-184.
  • Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D & Judson IR (2000) . Journal of Clinical Oncology, 18(10), 2081-2086.
  • Coleman RE (2000) . Breast Cancer, 7(4), 361-369.
  • Sharma S, Jagdev S, Coleman RE, Hancock BW & Lorigan PC (1999) . Br J Cancer, 81(6), 1037-1041.
  • Gillespie AM & Coleman RE (1999) . Cancer Treat Rev, 25(4), 219-227.
  • Abbey ME, Hancock BW & Coleman RE (1999) Calman-Hine and the new funding systems in the oncology setting, implementation and progress in North Trent.. BRIT J CANCER, 80, 70-70.
  • Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R , Thomas H et al (1999) . Journal of Clinical Oncology, 17(7), 2069-2069.
  • Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, Wildiers J, Michel J, Leonard R, Nortier J , Mignolet F et al (1999) . British Journal of Cancer, 80(1-2), 221-228.
  • Coleman RE (1999) Bisphosphonates in the prevention and treatment of metastatic bone disease. BREAST, 8(2), 57-62.
  • Robertson JFR, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury JRC , Gronberg H et al (1999) . European Journal of Cancer, 35(1), 47-53.
  • Gillespie AM, Siddiqui N, Coleman RE & Hancock BW (1999) . Br J Cancer, 79(7-8), 1270-1272.
  • Dobson LS, Gillespie AM, Coleman RE & Hancock BW (1999) . Br J Cancer, 79(9-10), 1531-1533.
  • Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, Quinn KJ & Kanis J (1999) . Ann Oncol, 10(3), 311-316.
  • Possinger K, Kaufmann M, Coleman R, Stuart NSA, Helsing M, Ohnmacht U & Arning M (1999) . Anti-Cancer Drugs, 10(2), 155-162.
  • (1999) . Cancer Treatment Reviews, 25(6), 321-321.
  • Coleman RE (1999) The management and clinical course of testicular seminoma: 15 years' experience at a single institution - Reply. CLIN ONCOL-UK, 11(2), 137-137.
  • Rubens RD & Coleman RE (1999) . Cancer Treatment Reviews, 25(1), 1-2.
  • (1999) . European Journal of Surgical Oncology (EJSO), 25(1), 3-23.
  • Adams M, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD , Harper PG et al (1998) Chemotherapy for ovarian cancer - a consensus statement on standard practice. BRIT J CANCER, 78(11), 1404-1406.
  • Coleman RE & Rubens RD (1998) Untitled - Reply to the letter from Robertson to Blamey. BRIT J CANCER, 78(10), 1397-1397.
  • Awada A, Cufer T, Beex L, Coleman R, Paridaens R, Bruning P, Klijn J, Nooij M, Mauriac L, Van Vreckem A , Biganzoli L et al (1998) . European Journal of Cancer, 34, S21-S21.
  • Hamilton A, Coleman R, Mauriac L, Awada A, Piccart M, Van Vreckem A & Bruning P (1998) . European Journal of Cancer, 34, S19-S19.
  • Gillespie AM, Rodgers S, Wilson AP, Tidy J, Rees RC, Coleman RE & Murray AK (1998) . Br J Cancer, 78(6), 816-821.
  • Coleman RE (1998) How can we improve the treatment of bone metastases further?. Curr Opin Oncol, 10 Suppl 1, S7-13.
  • Coleman RE, Houston S, Purohit OP, Rubens RD, Kandra A & Ford J (1998) . Eur J Cancer, 34(6), 820-824.
  • Coleman RE (1998) . Eur J Cancer, 34(2), 252-259.
  • Robertson JFR, Bombardieri E, Molina R, Coleman R & Jonsson P-E (1998) . Tumori Journal, 84(1), 104-105.
  • Robertson JFR & Blamey RW (1998) . British Journal of Cancer, 78(10), 1397-1397.
  • Krishnan E & Coleman RE (1998) . Clin Oncol (R Coll Radiol), 10(4), 246-249.
  • Coleman JM, Coleman RE, Turner AR, Radstone CR & Champion AE (1998) . Clin Oncol (R Coll Radiol), 10(4), 237-241.
  • Coleman RE, Smith P & Rubens RD (1998) . Br J Cancer, 77(2), 336-340.
  • Coleman RE (1998) Pamidronate disodium in the treatment and management of hypercalcaemia. REV CONTEMP PHARMACO, 9(3), 147-164.
  • Mountney J, Maury AC, Jackson AM, Coleman RE & Johnson AG (1997) . Eur J Surg Oncol, 23(6), 574-576.
  • Vinholes JJ, Purohit OP, Abbey ME, Eastell R & Coleman RE (1997) . Ann Oncol, 8(12), 1243-1250.
  • Gillespie AM, Lorigan PC, Radstone CR, Waterhouse JC, Coleman RE & Hancock BW (1997) . Br J Cancer, 76(10), 1382-1386.
  • Coleman RE, Purohit OP, Vinholes JJ & Zekri J (1997) . Cancer, 80(8 Suppl), 1686-1690.
  • Coleman RE (1997) . Cancer, 80(8 Suppl), 1588-1594.
  • Leonard RC, Smith IE, Coleman RE, Malpas JS, Nicolson M, Cassidy J, Jones A, McIllmurray MB, Stuart NS, Woll PJ & Whitehouse JM (1997) More money is needed to care for patients with cancer.. BMJ, 315(7111), 811-812.
  • El-Helw L, Lorigan PC, Coleman RE & Hancock BW (1997) . European Journal of Cancer, 33, S266-S266.
  • Robertson JFR, Kramer S, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury R , Blarney RW et al (1997) . The Breast, 6(4), 234-234.
  • ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M , Bolis G et al (1997) . Journal of Clinical Oncology, 15(6), 2183-2193.
  • Coleman R (1997) . Cancer Treatment Reviews, 23, S69-S75.
  • Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A & Van Glabbeke M (1997) . Journal of Clinical Oncology, 15(9), 3149-3155.
  • Rustin GJ, Nelstrop AE, Crawford M, Ledermann J, Lambert HE, Coleman R, Johnson J, Evans H, Brown S & Oster W (1997) . Journal of Clinical Oncology, 15(1), 172-176.
  • Vinholes J, Guo CY, Purohit OP, Eastell R & Coleman RE (1997) . J Clin Oncol, 15(1), 131-138.
  • Body JJ, Coleman RE & Piccart M (1996) Use of bisphosphonates in cancer patients. CANCER TREAT REV, 22(4), 265-287.
  • Kent G, Wills G, Faulkner A, Parry G, Whipp M & Coleman R (1996) . Patient Education and Counseling, 28(2), 187-190.
  • Vinholes J, Coleman R & Eastell R (1996) . Cancer Treatment Reviews, 22(4), 289-331.
  • Lorigan PC, Grierson AJ, Goepel JR, Coleman RE & Goyns MH (1996) . Cancer Lett, 104(1), 27-30.
  • Coleman R (1996) The management of advanced breast cancer. Current Practice in Surgery, 8(1), 7-12.
  • Vinholes J, Guo CY, Purohit OP, Eastell R & Coleman RE (1996) . Br J Cancer, 73(9), 1089-1095.
  • Reid RH, Hoskin P, Ell P, Coleman R & Quick D (1996) . Nuclear Medicine Communications, 17(4), 258-258.
  • Lorigan PC, Crosby T & Coleman RE (1996) . Drugs, 51(4), 571-584.
  • Highley MS, Samandas N, Ziras N, Morgan MM, Hill ME, Stein R, Barker S, Coleman RE, Blake PR, Morris D , Slevin ML et al (1996) . International Journal of Gynecological Cancer, 6(4), 323.
  • Coleman RE (1996) . European Journal of Cancer, 32, 44-44.
  • Vinholes APB & Coleman RE (1996) . European Journal of Cancer, 32, 51-51.
  • Vinholes J, Coleman R, Lacombe D, Mignolet F, Rose C, Leonard R, Nortier J & Tuibiana-Hulin M (1996) . European Journal of Cancer, 32, 50-50.
  • Zekri I, Vinholes J, Purohit O & Coleman R (1996) . European Journal of Cancer, 32, 52-52.
  • Coleman R, Purohit K & Vinholes J (1996) . Progress in Palliative Care, 4(2), 39-43.
  • Highley MS, Samandas N, Ziras N, Morgan MM, Hill ME, Stein R, Barker S, Coleman RE, Blake PR, Morris D , Slevin ML et al (1996) . International Journal of Gynecological Cancer, 6(4), 323-327.
  • Coleman RE, Purohit OP & Vinholes JJ (1996) . Acta Oncol, 35 Suppl 5, 23-29.
  • Sheridan E, Lorigan PC, Goepel J, Radstone DJ & Coleman RE (1996) . Clin Oncol (R Coll Radiol), 8(2), 102-105.
  • Vinholes J, Vinholes APB & Coleman RE (1996) Imaging of metastatic bone disease. Imaging, 8(3), 256-273.
  • Coleman RE (1995) Clinically available evaluation of bone disease in breast cancer--validity and cost effectiveness.. Can J Oncol, 5 Suppl 1, 69-79.
  • Lorigan PC, Nevin J, Radstone C, Coleman RE & Hancock BW (1995) . European Journal of Cancer, 31, S244-S244.
  • Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Awada A, Selleslags J, Van Vreckem A & Van Glabbeke M (1995) . European Journal of Cancer, 31, S75-S75.
  • Rustin GJS, Crawford SM, Coleman RE, Lambert J, Ledermann JA, Soukop M, Karp S, Phillips RH, Habboubi N & Meely K (1995) . European Journal of Cancer, 31, S109-S110.
  • Possinger K, Kaufmann M, Helsing M, Coleman R & Blatter J (1995) . European Journal of Cancer, 31, S80-S80.
  • Vinholes J, Purohit OP, Guo CY, Eastell R, Vinholes AP & Coleman R (1995) . European Journal of Cancer, 31, S253-S253.
  • Adams M, Mort D, Coleman R, Williams L, Evans A & Thompson M (1995) . European Journal of Cancer, 31, S106-S106.
  • Purohit OP, Radstone CR, Anthony C, Kanis JA & Coleman RE (1995) . Br J Cancer, 72(5), 1289-1293.
  • Coleman RE, Rubens RD, Rose C, Purohit OP, Houston S & Ford J (1995) . The Breast, 4(3), 235-236.
  • Coleman RE, Purohit OP, Black C, Vinholes J, Kanis JA, Schlosser K, Huss H & Quinn KJ (1995) . The Breast, 4(3), 236-236.
  • Vinholes J, Guo CY, Purohit OP, Eastell R, Vinholes APB & Coleman R (1995) . The Breast, 4(3), 235-235.
  • Vinholes J & Coleman R (1995) . Annals of Oncology, 6(7), 713-720.
  • PARNIS FX, COLEMAN RE, HARPER PG, PICKERING D, TOPHAM C, WHITTINGTON JR & TEDESCHI M (1995) A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL-TRIAL ASSESSING THE TOLERABILITY AND EFFICACY OF GLUTATHIONE AS AN ADJUVANT TO ESCALATING DOSES OF CISPLATIN IN THE TREATMENT OF ADVANCED OVARIAN-CANCER. EUR J CANCER, 31A(10), 1721-1721.
  • LEONARD RCF, COLEMAN RE & LEWIS I (1995) STRATEGY NEEDED FOR ADOLESCENT PATIENTS WITH CANCER. BRIT MED J, 311(7001), 387-387.
  • Stewart A, McQuade B, Cronje JDE, Goedhals L, Gudgeon A, Corette L, Froger X, Tubiana-Hulin M, Laplaige P, Roberts JT , McRae J et al (1995) . Oncology, 52(3), 202-210.
  • Henderson MA, Danks JA, Powell GW, Barnes DM, Coleman RE, Rubens RD, Bennett RC & Martin TJ (1995) . The Breast, 4(2), 112-116.
  • COLEMAN RE (1994) THERAPEUTIC USE OF BISPHOSPHONATES IN ONCOLOGY. BRIT MED J, 309(6963), 1233-1233.
  • TWELVES CJ, DOBBS NA, CURNOW A, COLEMAN RE, STEWART AL, TYRRELL CJ, CANNEY P & RUBENS RD (1994) A PHASE-II, MULTICENTER, UK STUDY OF VINORELBINE IN ADVANCED BREAST-CANCER. BRIT J CANCER, 70(5), 990-993.
  • Purohit OP, Anthony C, Radstone CR, Owen J & Coleman RE (1994) . Br J Cancer, 70(3), 554-558.
  • O'Rourke NP, McCloskey EV, Rosini S, Coleman RE & Kanis JA (1994) . Br J Cancer, 69(5), 914-917.
  • Coleman RE (1994) . The Breast, 3(2), 73-78.
  • Verweij J, Judson I, Steward W, Coleman R, Woll P, van Pottelsberghe C, van Glabbeke M & Mouridsen H (1994) . European Journal of Cancer, 30(6), 842-843.
  • Coleman RE & Purohit OP (1993) . Cancer Treat Rev, 19(1), 79-103.
  • COLEMAN R (1993) . Clinical Oncology, 5(5), 333-333.
  • Richards MA, Coleman RE, Hamsa R, Khaled H, Gad El Mawla M, Kadry I, Hablas A, Ramadan M, Allen D, Wang DY , Rubens RD et al (1992) Advanced breast cancer in Egyptian women: Clinical features and response to endocrine therapy. The Anglo-Egyptian Health Agreement Collaborative Study. European Journal of Surgical Oncology, 18(3), 219-223.
  • Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RCF & Ford J (1992) . British Journal of Cancer, 65(5), 766-768.
  • Soukop M, McQuade B, Hunter E, Stewart A, Kaye S, Cassidy J, Kerr D, Khanna S, Smyth J, Coleman R , Cunningham D et al (1992) . Oncology, 49(4), 295-304.
  • Kamthan A, Scarffe JH, Walling J, Hatty S, Peters B, Coleman R & Smyth JF (1992) . Anti-Cancer Drugs, 3(4), 331-336.
  • Coleman RE (1992) . Biotherapy, 4(1), 37-44.
  • Daley-Yates PT, Dodwell DJ, Pongchaidecha M, Coleman RE & Howell A (1991) . Calcified Tissue International, 49(6), 433-435.
  • Coleman RE (1991) Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.. Oncology (Williston Park), 5(8), 55-60.
  • Coleman R, Leonard R, Cornbleet M, Gregor A, Newaishy G, Greening A, Crompton G, Stewart M & Smyth J (1991) . Lung Cancer, 7(5), 299-307.
  • Coleman RE, Dirix LY, Dodwell D, Tubiana-Hulin M, Body J-J, Becher R, White GK, Rubens RD, Van Oosterom A, Howell A & Ford J (1991) . European Journal of Cancer and Clinical Oncology, 27(7), 945-946.
  • Smyth JF, Coleman RE, Nicolson M, Gallmeier WM, Leonard RC, Cornbleet MA, Allan SG, Upadhyaya BK & Bruntsch U (1991) . BMJ, 303(6815), 1423-1426.
  • WHILLIS D, COLEMAN RE, LESSELLS AM, HARGREAVE TB, CORNBLEET MA & HOWARD GCW (1991) . British Journal of Urology, 68(3), 292-295.
  • Thompson P, Wilson P, Osborne R, Slevin M, Wiltshaw F, Blake P, Harper P, Coleman R, Williams C, Sweetenham J , Young A et al (1991) . British Journal of Cancer, 64(5), 973-974.
  • Coleman RE, Twelves CJ, O'Reilly SM, Rubens RD, Richards MA & Harper PG (1991) . European Journal of Cancer and Clinical Oncology, 27(8), 1062-1063.
  • Whillis D, Coleman RE, Cornbleet MA & Howard GCW (1991) . Clinical Oncology, 3(3), 141-146.
  • COLEMAN RE, WHILLIS D, HOWARD GCW, TAYLOR RE & CORNBLEET MA (1991) . British Journal of Urology, 68(3), 296-300.
  • Coleman RE, Fogelman I, Habibollahi F, North WRS & Rubens RD (1990) . Clinical Oncology, 2(6), 328-332.
  • Coleman RE, Clarke JM, Slevin ML, Sweetenham J, Williams CJ, Blake P, Calman F, Wiltshaw E & Harper PG (1990) . Cancer Chemotherapy and Pharmacology, 27(1), 52-54.
  • Coleman R, Towlson K, Wiltshaw E, Slevin M, Blake P, Stein R, Coombes R & Harper P (1990) . European Journal of Cancer and Clinical Oncology, 26(7), 850-851.
  • Coleman R, Clarke J, Gore M, Wiltshaw E, Slevin M & Harper P (1989) . Cancer Chemotherapy and Pharmacology, 24(3), 200-202.
  • Gallagher C, Wiltshaw E, Coleman R & Harper P (1989) . Cancer Chemotherapy and Pharmacology, 24(1).
  • Boxer DI, Todd CEC, Coleman R & Fogelman I (1989) Bone secondaries in breast cancer: The solitary metastasis. Journal of Nuclear Medicine, 30(8), 1318-1320.
  • O'Reilly SM, Coleman RE & Rubens RD (1989) . Cancer Chemotherapy and Pharmacology, 25(1), 73-74.
  • Twelves CJ, O'Reilly SM, Coleman RE, Richards MA & Rubens RD (1989) . British Journal of Cancer, 60(6), 938-941.
  • Coleman RE, Woll PJ, Miles M, Scrivener W & Rubens RD (1988) . British Journal of Cancer, 58(5), 621-625.
  • Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW & Rubens RD (1988) . European Journal of Cancer and Clinical Oncology, 24(7), 1211-1217.
  • Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman I & Rubens RD (1988) . British Journal of Cancer, 58(2), 205-210.
  • Rubens RD, Tinson CL, Coleman RE, Knight RK, Tong D, Winter PJ & North WRS (1988) . British Journal of Cancer, 58(5), 626-630.
  • Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD & Fogelman I (1988) Bone scan flare predicts successful systemic therapy for bone metastases. Journal of Nuclear Medicine, 29(8), 1354-1359.
  • Coleman RE, Meier CA, Rubens RD & Fogelman I (1988) Comparison of99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer. Nuclear Medicine Communications, 9(7), 481-485.
  • Coleman RE, Fogelman I & Rubens RD (1988) Hypercalcaemia and breast cancer - An increased humoral component in patients with liver metastases. European Journal of Surgical Oncology, 14(5), 423-428.
  • Coleman RE, Rubens RD & Fogelman I (1988) Reappraisal of the baseline bone scan in breast cancer. Journal of Nuclear Medicine, 29(6), 1045-1049.
  • Coleman RE, Fogelman I & Rubens RD (1987) . Bone, 8(4), 267-267.
  • Coleman RE & Rubens RD (1987) . British Journal of Cancer, 55(1), 61-66.
  • Coleman RE & Rubens RD (1987) . British Journal of Cancer, 56(4), 465-469.
  • Coleman RE, Harper PG, Gallagher C, Osborne R, Rankin EM, Silverstone AC, Slevin ML, Souhami RL, Tobias JS, Trask CW & Wiltshaw E (1986) . Cancer Chemotherapy and Pharmacology, 18(3).
  • Mouridsen HT, Cornbleet M, Stuart-Harris R, Smith I, Coleman R, Rubens R, McDonald M, Rainer H, van Oosterom A & Smyth J (1985) . Investigational New Drugs, 3(2), 139-148.
  • Coleman RE & Rubens RD (1985) . Cancer Treatment Reviews, 12(4), 251-270.
  • Coleman RE, Maisey MN, Knight RK & Rubens RD (1984) . European Journal of Cancer and Clinical Oncology, 20(6), 771-776.
  • Smyth JF, Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, Mouridsen HT, Rainer H & van Oosterom AT (1984) Mitoxantrone as first-line chemotherapy for advanced breast cancer: Results of a European collaborative study. Seminars in Oncology, 11(3 SUPPL. 1), 15-18.
  • Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, Mouridsen HT, Rainer H, Van Oosterom AT & Smyth JF (1984) . European Journal of Cancer and Clinical Oncology, 20(9), 1141-1146.
  • Probert J, Dodwell D, Broggio J, Coleman R, Marshall H, Darby SC & Mannu GS () . BJC Reports, 3(1).
  • O’Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell’Orto P, Lang I, Bellet M, Bonnefoi HR , Tondini C et al () . JAMA Oncology.
  • Brown J, Paggiosi MA, Rathbone E, Gregory W, Bertelli G, Din O, McCloskey E, Dodwell D, Cameron D, Eastell R & Coleman R () . Journal of Bone and Mineral Research.
  • Coleman R () . Journal of Bone and Mineral Metabolism.
  • Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B , Burstein HJ et al () . Journal of Clinical Oncology.
  • Coleman R () . Cancers, 14(15), 3640-3640.
  • Lovero D, D’Oronzo S, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C, Lauricella E, Coleman R & Silvestris F () . British Journal of Cancer.
  • Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S , Denkert C et al () . JAMA Oncology.
  • Coleman R, Zhou Y, Jandial D, Cadieux B & Chan A () . Advances in Therapy.
  • Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J , Jückstock J et al () . JAMA Oncology.
  • Singh K, Gillett S, Ireson J, Hills A, Tidy JA, Coleman RE, Hancock BW & Winter MC () . International Journal of Cancer.
  • Wilson C, Nutter F, Brown H, Coleman R & Holen I () . Bone Abstracts.
  • Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW & Lawrie TA () . Cochrane Database of Systematic Reviews.
  • Greenfield D, Blewitt A, Coleman R, Walsh J, Snowden J, Ross R & Han T () . Endocrine Abstracts.
  • Burkinshaw R, Thorpe H & Coleman R () . Breast Cancer Online, 10(11).
  • Papazisis KT, Habeshaw T & Miles DW () . International Journal of Clinical Practice, 58(6), 581-586.
  • Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J , Reed NS et al () . British Journal of Cancer, 84(2), 170-178.

Book chapters

  • Coleman R (2024) , Reference Module in Biomedical Sciences Elsevier
  • Coleman R (2022) , Bone Cancer (pp. 957-966). Elsevier
  • Coleman RE, Brown J & Holen I (2020) , Abeloff's Clinical Oncology (pp. 809-830.e3). Elsevier
  • Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020) Springer Science and Business Media LLC
  • Coleman R (2019) , Management of Breast Cancer in Older Women (pp. 193-218). Springer International Publishing
  • Coleman R (2019) , Encyclopedia of Endocrine Diseases (pp. 320-328). Elsevier
  • Chow E, Finkelstein JA, Sahgal A & Coleman RE (2018) Metastatic cancer to the bone, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (pp. 1970-1982).
  • Wilson C, Taylor F & Coleman R (2018) , Side Effects of Medical Cancer Therapy (pp. 439-460). Springer International Publishing
  • Coleman R (2015) , Bone Cancer (pp. 677-683). Elsevier
  • Chow E, Finkelstein JA, Sahgal A & Coleman RE (2015) Metastatic cancer to the bone, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Tenth Edition
  • Coleman R (2015) , Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition (pp. 677-683).
  • Coleman RE (2014) Adjuvant systemic therapy: Bone-targeted treatments, Diseases of the Breast: Fifth Edition
  • Coleman RE & Holen I (2014) , Abeloff's Clinical Oncology (pp. 739-763.e3). Elsevier
  • Coleman RE & Holen I (2013) , Abeloff's Clinical Oncology: Fifth Edition (pp. 739-763).
  • Adler RA, Anderson DE, Arabi A, Arnett TR, Bachrach LK, Ballane G, Baran D, Barnes GL, Baron R, Bauer DC , Bauman WA et al (2013) , Osteoporosis (pp. xix-xxiii). Elsevier
  • Wilson C, Taylor FG & Coleman RE (2013) , Side Effects of Medical Cancer Therapy (pp. 531-567). Springer London
  • Lipton A, Dansey R & Coleman R (2013) , Osteoporosis (pp. 1445-1454). Elsevier
  • Abbruzzese JL, Abeloff MD, Abou-Alfa GK, Abrahm JL, Abrams JS, Acs G, Aisner J, Aisner SC, Alani RM, Alberts SR , Ambinder RF et al (2008) , Abeloff's Clinical Oncology (pp. xi-xxvi). Elsevier
  • Coleman RE & Holen I (2008) , Abeloff's Clinical Oncology (pp. 845-871). Elsevier
  • Coleman RE & Croucher PI (2006) , Textbook of Bone Metastases (pp. 41-50).
  • Vinholes J & Coleman R (1997) , The Teaching Cases from Annals of Oncology (pp. 29-36). Springer Netherlands
  • Alazzam M, Tidy J, Osborne R, Coleman R & Hancock BW () John Wiley & Sons, Ltd
  • Coleman RE & Neville-Webbe HL () , Textbook of Bone Metastases (pp. 387-397). John Wiley & Sons, Ltd
  • Coleman RE, Cook GJR & Fogelman I () , Textbook of Bone Metastases (pp. 77-90). John Wiley & Sons, Ltd
  • Coleman RE () , Textbook of Bone Metastases (pp. 377-385). John Wiley & Sons, Ltd
  • Coleman RE & Ralston SH () , Textbook of Bone Metastases (pp. 351-360). John Wiley & Sons, Ltd
  • Coleman RE, Plunkett TA & Rubens RD () , Textbook of Bone Metastases (pp. 63-75). John Wiley & Sons, Ltd
  • Coleman RE, Gwyn K & Theriault R () , Textbook of Bone Metastases (pp. 361-368). John Wiley & Sons, Ltd
  • Coleman RE, Guillevin R, Vallée JN, Martin-Duverneuil N, Lo D, Lafitte F, Maillard JC & Chiras J () , Textbook of Bone Metastases (pp. 91-104). John Wiley & Sons, Ltd
  • Coleman RE & Dunstan CR () , Textbook of Bone Metastases (pp. 51-62). John Wiley & Sons, Ltd
  • Coleman RE & Berenson JR () , Textbook of Bone Metastases (pp. 369-376). John Wiley & Sons, Ltd
  • Coleman RE & Rogers MJ () , Textbook of Bone Metastases (pp. 323-343). John Wiley & Sons, Ltd
  • Coleman RE & Eccles SA () , Textbook of Bone Metastases (pp. 1-25). John Wiley & Sons, Ltd
  • Coleman RE, Martin TJ, Danks JA & Henderson MA () , Textbook of Bone Metastases (pp. 27-39). John Wiley & Sons, Ltd
  • Coleman RE, Salai M & Dudkiewicz I () , Textbook of Bone Metastases (pp. 123-131). John Wiley & Sons, Ltd
  • Coleman RE & Brown JE () , Textbook of Bone Metastases (pp. 105-121). John Wiley & Sons, Ltd
  • Coleman RE & Clézardin P () , Textbook of Bone Metastases (pp. 345-350). John Wiley & Sons, Ltd

Conference proceedings

  • Coleman RE, Fried G, Kim S-B, Kuchuk I, Kiesl D, Ramos M, Sohn J, Siegel J, Li R, Uema D , Wagner V et al (2021) (pp ps14-01-ps14-01)
  • Coleman R (2021) MANAGEMENT OF BONE DISEASE IN CANCER. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S37-S38)
  • Coleman R (2021) INFLUENCE OF ADJUVANT BISPHOSPHONATES AND DENOSUMAB ON BREAST CANCER OUTCOMES. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S93-S93)
  • Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. CANCER RESEARCH, Vol. 81(4)
  • Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, Neven P, Stierer M, Holcombe C, Coleman R , Forbes J et al (2021) 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. CANCER RESEARCH, Vol. 81(4)
  • Stavraka C, Evans TRJ, Dunlop J, Earl H, Cameron DA, Coleman RE, Perren T, Leonard RCF & Mansi JL (2020) . Poster Session Abstracts
  • Coleman R (2019) . The Breast, Vol. 44 (pp S12-S12)
  • Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) . Poster Session Abstracts
  • Coleman R, Gregory W, Jean-Mairet J, Tercero JC, Torres-Martin J & Gomis R (2019) . Cancer Research, Vol. 79(4_Supplement)
  • Gee J, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K , Rauchhaus P et al (2019) . Poster Session Abstracts
  • Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) . Early Clinical Opportunities
  • Coleman RE, Finkelstein D, Barrios CH, Martin M, Iwata H, Glaspy JA, Zhou Y, Jandial D & Chan A (2018) . Journal of Clinical Oncology, Vol. 36(15_suppl) (pp 501-501)
  • Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Kelly S , Horgan K et al (2018) . Poster Session Abstracts
  • Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S , Denkert C et al (2018) . General Session Abstracts
  • Janni W, Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Bauer E, Fink V , Bekes I et al (2018) . General Session Abstracts
  • Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S , Denkert C et al (2018) A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial). CANCER RESEARCH, Vol. 78(4)
  • Janni W, Friedl TWP, Fehm T, Mueller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Bauer E, Fink V , Bekes I et al (2018) Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study. CANCER RESEARCH, Vol. 78(4)
  • Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence.. MOLECULAR CANCER RESEARCH, Vol. 16(8) (pp 68-69)
  • Sestak I, Cuzick J, Blake G, Patel R, Coleman R & Eastell R (2018) Off-treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 46-46)
  • Friedl TWP, Rack B, Fehm T, Mueller V, Lichtenegger W, Blohmer J-U, Lorenz R, Forstbauer H, Bauer E, Fink V , Bekes I et al (2018) Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: results from the phase III Success A study. ONCOLOGY RESEARCH AND TREATMENT, Vol. 41 (pp 32-32)
  • Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Kelly S , Horgan K et al (2018) AZD5363, AN AKT INHIBITOR, SIGNIFICANTLY INHIBITS KEY BIOMARKERS OF THE AKT PATHWAY AND KI67, IN A RANDOMIZED, PLACEBO, CONTROLLED STUDY (STAKT) IN HUMAN BREAST CANCERS. BRITISH JOURNAL OF SURGERY, Vol. 105 (pp 24-24)
  • Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Kelly S , Horgan K et al (2018) AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers. CANCER RESEARCH, Vol. 78(4)
  • Goyal A, Coleman RE, Dodwell D, Fallowfield L, Jenkins VA, Mann B & Reed MW (2017) . Ongoing Clinical Trials
  • Rugo HS, Drumea KC, Campone M, Barnadas A, Petrenciuc O, Zhang A, Li R & Coleman RE (2017) . Ongoing Clinical Trials
  • Coleman RE, Fried G, Petrenciuc O, Sawhney A, Li R & Rugo HS (2017) . Ongoing Clinical Trials
  • Roberston JFR, Cheung KL, Ahmed S, Coleman RE, Evans A, Holcombe C, Rea D, Rauchhaus P, Skene A, Littleford R , Jahan A et al (2017) . Poster Session Abstracts
  • Coleman R, Hall A, Bell R, Cameron D, Marshall H, Jean-Mairet J, Tercero J, Rojo F, Albanell J & Gomis R (2017) . Poster Session Abstracts
  • Yardley D, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J , Schneeweiss A et al (2017) . Poster Session Abstracts
  • Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J & Thorat MA (2017) Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial. TRIALS, Vol. 18
  • Rugo H, Petrenciuc O, Zhang A, Li R & Coleman RE (2016) . Annals of Oncology, Vol. 27 (pp vi97-vi97)
  • Coleman RE (2016) ADDITIVE EFFECTS OF ANTIRESORPTIVE TREATMENTS BEYOND OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S563-S563)
  • Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P , Stierer M et al (2016) . General Session Abstracts
  • Coleman RE, Huang L, Petrenciuc O, Zaccarini P & Rugo HS (2016) . Ongoing Clinical Trials
  • Rugo HS, Huang L, Petrenciuc O, Zaccarini P & Coleman RE (2016) . Ongoing Clinical Trials
  • Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H , Liefers GJ et al (2016) . European Journal of Cancer, Vol. 54 (pp 57-63)
  • Amadori D, Rossetti C, Aglietta M, Messina C, Versari A, Vogelzang NJ, Sartor A, Coleman RE, Govi S, Fang F , Skjorestad I et al (2015) 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. ANNALS OF ONCOLOGY, Vol. 26 (pp 55-55)
  • Sartor O, Coleman RE, Morris MJ, Nilsson S, Shore N, Sweeney C, Vogelzang NJ, Petrenciuc O, Gratt J & Parker C (2015) . European Journal of Cancer, Vol. 51 (pp S484-S485)
  • Sartor O, Coleman RE, Nilsson S, Vogelzang NJ, Staudacher K, Thuresson M & Parker C (2015) . European Journal of Cancer, Vol. 51 (pp S477-S477)
  • Parker C, Vogelzang NJ, Sartor AO, Coleman RE, Skjorestad I, Fang F & Nilsson S (2015) . Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e16102-e16102)
  • Goyal A, Coleman RE, Dodwell DJ, Fallowfield L, Jenkins VA, Mann B & Reed MW (2015) . Journal of Clinical Oncology, Vol. 33(15_suppl) (pp TPS1103-TPS1103)
  • Coleman RE, Huang L, Petrenciuc O & Zaccarini P (2015) . Journal of Clinical Oncology, Vol. 33(15_suppl) (pp TPS1104-TPS1104)
  • Yardley DA, Cortes J, Coleman RE, Conte PF, Brufsky A, O'Shaughnessy J, Wright GLS, Eakle JF, Wilks S, Shtivelband M , Young RR et al (2015) . Journal of Clinical Oncology, Vol. 33(15_suppl) (pp TPS1106-TPS1106)
  • Goldhirsch A, Gelber RD, Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos EM, Bellet M, Bonnefoi H, Climent MA , Pavesi L et al (2015) . General Session Abstracts
  • Giobbie-Hurder A, Thürlimann B, Ejlertsen B, Neven P, Coleman RE, Smith I, Wardley AM, Láng I, Colleoni M, Debled M , Forbes JF et al (2015) . Poster Session Abstracts
  • Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Liefers G-J, Winter MC, Weilbaecher KN, Akazawa K, Hinsley S , Putter H et al (2015) . Poster Session Abstracts
  • Yardley DA, Coleman RE, Conte P, O'Shaughnessy J, Cortes J, Glück S, Brufsky A, Nabholtz J-MA, Li L, Miller J , Barton D et al (2015) . Ongoing Clinical Trials
  • Parker C, Vogelzang NJ, Sartor AO, Coleman RE, Fang F, Skjorestad I & Nilsson S (2015) . Journal of Clinical Oncology, Vol. 33(7_suppl) (pp 195-195)
  • Parker C, Vogelzang N, Sartor O, Bottomley D, Coleman RE, Skjorestad I, Aksnes A, Wahba M & Nilsson S (2014) . Annals of Oncology, Vol. 25 (pp iv263-iv263)
  • Parker C, Vogelzang NJ, Sartor AO, Bottomley D, Coleman RE, Skjorestad I, Wahba M & Nilsson S (2014) . Journal of Clinical Oncology, Vol. 32(15_suppl) (pp 5070-5070)
  • Klotz L, Smith MR, Coleman RE, Pittman KB, Milecki P, Wei R, Balakumaran A & Fizazi K (2014) . Journal of Clinical Oncology, Vol. 32(15_suppl) (pp 5075-5075)
  • Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz J-MA, O'Shaughnessy J, Li L, Barton D , Beck RM et al (2014) . Journal of Clinical Oncology, Vol. 32(15_suppl) (pp TPS1146-TPS1146)
  • Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M, Forbes JF, Singh S & Cuzick J (2014) EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II). OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S281-S281)
  • Velikova G, Barrett-Lee P, Bloomfield D, Brunt M, Canney P, Coleman R, Morden J, Sergenson N, Verill M, Wardley A , Bliss J et al (2014) Quality of life results of the UK TACT2 Trial: More intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). EUROPEAN JOURNAL OF CANCER, Vol. 50 (pp S109-S109)
  • Canney P, Barrett-Lee P, Bartlett J, Bertelli G, Coleman R, Earl H, Ellis P, Morden J, Murray N, Stein R , Cameron D et al (2014) The UK TACT2 Trial: Non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). EUROPEAN JOURNAL OF CANCER, Vol. 50 (pp S99-S100)
  • Pittman K, Smith M, Coleman R, Klotz L, Milecki P, Wei R, Balakumaran A & Fizazi K (2014) Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: a comparison with skeletal-related events. BJU INTERNATIONAL, Vol. 113 (pp 23-23)
  • Sanganalmath P, Purohit K, Winter M, Horsman J, Ramakrishnan S, Hatton M, Lee C, Dunn K, Din O & Coleman R (2014) Eribulin monotherapy in heavily pre-treated patients with advanced breast cancer: "Real world" experience. EUROPEAN JOURNAL OF CANCER, Vol. 50 (pp S181-S182)
  • Sestak I, Singh S, Cuzick J, Blake G, Patel R, Coleman R, Dowsett M, Forbes JF, Howell A & Eastell R (2014) Risedronate Prevents Anastrozole-Induced Bone Loss In The IBIS-II Prevention Trial.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S110-S110)
  • Smith MR, Coleman RE, Klotz L, Pittman KB, Milecki P, Wei R, Balakumaran A & Fizazi K (2014) . Journal of Clinical Oncology, Vol. 32(4_suppl) (pp 35-35)
  • Nilsson S, Vogelzang NJ, Sartor AO, Bottomley D, Coleman RE, Skjorestad I, Wahba M & Parker C (2014) . Journal of Clinical Oncology, Vol. 32(4_suppl) (pp 9-9)
  • Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Zhou Y, Maniar T & Coleman RE (2013) . Ongoing Trials Poster Session Abstracts
  • Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Marshall H, Banks RE, Selby PJ, Coleman RE & Brown JE (2013) . Poster Session Abstracts
  • Coleman R, Gnant M, Paterson A, Powles T, von Minckwitz G, Pritchard K, Bergh J, Bliss J, Gralow J, Anderson S , Evans V et al (2013) . General Session Abstracts
  • Coleman RE (2013) . ANNALS OF ONCOLOGY, Vol. 24 (pp 26-26)
  • Stroelin P, Haese A, Heinzer H, Steuber T, Sartor O, Coleman RE, Nilsson S, Vogelzang N, Cross A, O'Bryan-Tear G , Staudacher K et al (2013) Safety of cytotoxic chemotherapy following Radium223-Dichlorid(Ra223)-therapy in the phase 3 ALSYMPCA study in patients with castration resistant prostate cancer (CRPC) metastatic to the bone. ONKOLOGIE, Vol. 36 (pp 20-20)
  • Steuber T, Heinzer H, Haese A, Stroelin P, Parker C, Coleman RE, Nilsson S, Vogelzang N, Loyd AJ, Staudacher K , van Gool R et al (2013) Updated Survival, Quality of life (QOL) and Safety-data of Radium223 Dichlorid (Ra223) in patients with castration resistant prostate cancer (CRPC) with bone metastasis from the Phase 3 double-blind randomised, multinational study (ALSYMPCA). ONKOLOGIE, Vol. 36 (pp 18-18)
  • Coleman R, Fossa S, Chodacki A, Wedel S, Bruland O, Staudacher K, Garcia-Vargas J & Sartor O (2013) Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S688-S688)
  • Coleman R (2013) Micro-environment and bone metastases. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S78-S78)
  • Wiechno P, Helle SI, Logue J, Nilsson S, Sartor O, Coleman RE, Kliment J, Fang F & Parker C (2013) Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S690-S691)
  • Sartor O, Coleman R, Nilsson S, Heinrich D, Staudacher K, Garcia-Vargas J & Vogelzang N (2013) Radium-223(Ra-223) safety and efficacy in prostate cancer with bone metastases: phase 3 ALSYMPCA study findings stratified by age. BJU INTERNATIONAL, Vol. 112 (pp 15-16)
  • Chan A, Goss P, Barrios C, Finkelstein DM, Iwata H, Martin M, Coleman R, Braun A, Zhou Y & Maniar T (2013) DENOSUMAB VERSUS PLACEBO AS ADJUVANT TREATMENT FOR WOMEN WITH EARLY-STAGE BREAST CANCER AT HIGH RISK OF DISEASE RECURRENCE (D-CARE). ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 9 (pp 53-53)
  • Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Ding B, Maniar T & Coleman RE (2013) Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
  • Coleman R (2013) BISPHOSPHONATES, BONE AND CANCER: MORE THAN INHIBITION OF BONE RESORPTION?. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S29-S29)
  • Saad F, Patrick DJ, Smith M, Cleeland C, Fallowfield L, Tombal B, Oudard S, Shore N, Marx G, Coleman R , Gomez-Veiga F et al (2013) The impact of bone metastases on pain: post-hoc analysis of a phase III study of denosumab in men with non-metastatic Castration-Resistant Prostate Cancer (CRPC). BJU INTERNATIONAL, Vol. 111 (pp 38-38)
  • Coleman RE (2013) THE METASTATIC MICROENVIRONMENT OF BREAST CANCER: CLINICAL IMPLICATIONS. BREAST, Vol. 22 (pp S7-S7)
  • Nilsson S, Sartor AO, Bruland OS, Fang F, Aksnes A-K & Parker C (2013) . Journal of Clinical Oncology, Vol. 31(6_suppl) (pp 19-19)
  • Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M, Forbes J, Singh S & Cuzick J (2013) Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
  • Coleman R (2012) . BREAST, Vol. 21 (pp S5-S5)
  • Parker C, Coleman RE, Nilsson S, Vogelzang N, Lloyd AJ, Staudacher K, van Gool R & Sartor AO (2012) UPDATED SURVIVAL, QUALITY OF LIFE (QOL), AND SAFETY DATA OF RADIUM-223 CHLORIDE (RA-223) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES FROM THE PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTINATIONAL STUDY (ALSYMPCA). ANNALS OF ONCOLOGY, Vol. 23 (pp 296-296)
  • Sartor O, Coleman RE, Nilsson S, Vogelzang N, Cross A, O'Bryan-Tear G, Staudacher K, Garcia-Vargas JE, Zou J & Parker C (2012) SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES. ANNALS OF ONCOLOGY, Vol. 23 (pp 308-309)
  • Coleman RE, Barrios C, Bell R, Finkelstein DM, Iwata H, Martin M, Braun A, Ke C, Maniar T & Goss PE (2012) DENOSUMAB VERSUS PLACEBO AS ADJUVANT TREATMENT FOR WOMEN WITH EARLY-STAGE BREAST CANCER AT HIGH RISK OF DISEASE RECURRENCE (D-CARE): AN IN PROGRESS, PHASE 3 CLINICAL TRIAL. ANNALS OF ONCOLOGY, Vol. 23 (pp 115-115)
  • Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A , Johannessen DC et al (2012) Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(18)
  • Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A , Johannessen DC et al (2012) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Gregory W, Marshall H, Bell R, Cameron DA & Coleman RE (2012) Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Sartor AO, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A, Johannessen DC , Nilsson S et al (2012) Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Marshall H, Gregory W, Bell R, Cameron DA, Dodwell DJ, Keane MM, Gil MJG, Davies C, Coleman RE & Investigators AZURE (2012) Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Leonard RCF, Adamson D, Bertelli G, McLinden M, Haiying N, Dunlop J, Mansi J, Coleman RE, Thomas G & Anderson R (2012) The relative value of anti-Mullerian hormone to predict premature menopause in patients receiving adjuvant chemotherapy for breast cancer: Results from the OPTION trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Goss PE, Barrios CH, Bell R, Finkelstein DM, Iwata H, Martin M, Braun AH, Ke C, Maniar T & Coleman RE (2012) Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP-K, Hayward L, Simmonds P, Waterhouse A, Marshall H & Investigators BISMARK (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Garcia A & Perez E (2012) SIGNIFICANT ANTITUMOR ACTIVITY IN A RANDOMIZED PHASE 2 STUDY COMPARING 2 SCHEDULES OF NKTR-102 IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC). ANNALS OF ONCOLOGY, Vol. 23 (pp 43-43)
  • Canney P, Coleman R, Morden J, Barrett-Lee P, Banerji J, Wardley A, Murray N, Laing R, Cameron D & Bliss J (2012) TACT2 Trial in Early Breast Cancer (EBC): Differential Rates of Amenorrhoea in Premenopausal Women Following Adjuvant Epirubicin (E) or Accelerated Epirubicin (aE) Followed by Capecitabine (X) or CMF (CRUK/05/019). EUROPEAN JOURNAL OF CANCER, Vol. 48 (pp S102-S102)
  • de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A & Coleman R (2011) . General Session Abstracts
  • Coleman RE (2011) . BREAST, Vol. 20 (pp S19-S20)
  • Coleman R, Marshall H, Gregory W, Bell R, Dodwell D, Keane M, Gil M, Davies C & Cameron D (2011) Discordant Treatment Effects According to Menopausal Status Following Adjuvant Zoledronic Acid in Stage II/III Breast Cancer - The AZURE Trial (BIG 01/04). EUROPEAN JOURNAL OF CANCER, Vol. 47 (pp S336-S336)
  • Bell R, Marshall H, Collinson M, Cameron D, Dodwell D, Keane M, Gil M, Davies C & Coleman R (2011) Reduction in Fractures Following Adjuvant Zoledronic Acid in Stage II/III Breast Cancer - the AZURE Trial (BIG 01/04). EUROPEAN JOURNAL OF CANCER, Vol. 47 (pp S376-S376)
  • Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) . BONE, Vol. 48 (pp S255-S255)
  • Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58)
  • Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
  • Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58)
  • Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
  • Shankland C & Coleman R (2011) The effect of zoledronic acid on bone mineral density and bone turnover in patients with early breast cancer on the AZURE trial. BREAST, Vol. 20 (pp S71-S71)
  • Hadji P, Body J, Bundred N, Brufsky A, Coleman R, Gnant M, Guise T, Lipton A & Aapro M (2011) Updated guidance for the prevention of aromatase inhibitor (AI)-associated bone loss (AIBL) in early breast cancer (EBC). BREAST, Vol. 20 (pp S84-S84)
  • Coleman R (2011) Is caring for the bone also fighting the breast cancer?. BREAST, Vol. 20 (pp S2-S2)
  • Coleman RE & Giordano SH (2011) Adjuvant treatment with zoledronic acid in stage II/III breast cancer: The AZURE trial. P and T, Vol. 36(3) (pp 156)
  • Winter MC, Evans A, Holen I & Coleman RE (2011) . BONE, Vol. 48(1) (pp S30-S31)
  • Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) . BONE, Vol. 48(1) (pp S33-S33)
  • Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) . BONE, Vol. 48(1) (pp S41-S41). Sheffield, ENGLAND, 22 September 2010 - 25 September 2010.
  • Ottewell PD, Brown H, Evans CA, Wind NS, Brown NJ, Coleman RE & Holen I (2011) . BONE, Vol. 48(1) (pp S42-S42)
  • Woodward EJ, Brown JE, Barnfield MC, Taylor J, Blake GM, Fogelman I, Turner LA, Thorpe H, Dodwell D, Joffe JK & Coleman RE (2011) . BONE, Vol. 48(1) (pp S29-S29)
  • Coleman RE, Woodward EJ, Brown JE, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R , Houston SJ et al (2011) . BONE, Vol. 48(1) (pp S29-S29)
  • Body J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2011) . BONE, Vol. 48(1) (pp S20-S21)
  • Singh S, Cuzick J, Blake GM, Mesher D, Patel R, Truscott J, Coleman R, Howell A, Forbes J & Eastell R (2011) . BONE, Vol. 48(1) (pp S24-S24)
  • Leonard R, Adamson D, Anderson R, Ballinger R, Bertelli G, Coleman R, Fallowfield L, Keerie C, McLinden M, Mansi J , Thomas G et al (2010) . Poster Session Abstracts
  • DeBoer R, Bundred N, Eidtmann H, Llombert A, Neven P, von Minckwitz G, Martin N, Modi A & Coleman R (2010) . Poster Session Abstracts
  • Holen I, Ottewell PD & Coleman RE (2010) . Poster Session Abstracts
  • Winter MC, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Mori S, Holen I & Coleman RE (2010) . Poster Session Abstracts
  • Huebner JL, Bay Jensen AC, Leeming DJ, Coleman RE, McDaniel G, Karsdal MA & Kraus VB (2010) . Osteoarthritis and Cartilage, Vol. 18 (pp S29-S30)
  • Coleman R (2010) SHOULD BONE TARGETED TREATMENT BE USED IN THE ADJUVANT SETTING?. ANNALS OF ONCOLOGY, Vol. 21 (pp 23-23)
  • Coleman R (2010) A clinician's perspective. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol. 37 (pp S278-S278)
  • Costa L, Cook R, Body J, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2010) . BONE, Vol. 47 (pp S302-S303)
  • Body J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2010) . BONE, Vol. 47 (pp S311-S312)
  • Brown J, Lipton A, Cook R, Michaelson D, Coleman R & Saad F (2010) . BONE, Vol. 47 (pp S312-S312)
  • Ottewell PD, Lefely DV, Cross SS, Coleman RE & Holen I (2010) . BONE, Vol. 47 (pp S317-S317)
  • Brown HK, Ottewell PD, Lefely DV, Coleman RE & Holen I (2010) . BONE, Vol. 47 (pp S318-S319)
  • Woodward EJ, Brown JE, Ellis SP, Gutcher S, Lester JE, Purohit O & Coleman RE (2010) . BONE, Vol. 47 (pp S310-S311)
  • Din OS, Brown JE, Ellis SP, Gutcher SA & Coleman RE (2010) . BONE, Vol. 47 (pp S311-S311)
  • Winter MC, Evans A, Holen I & Coleman RE (2010) . BONE, Vol. 47 (pp S310-S310)
  • Coleman R (2010) . BONE, Vol. 46 (pp S18-S18)
  • Coleman R (2010) Partnership approach to clinical research in the UK. EJC SUPPLEMENTS, Vol. 8(3) (pp 59-59)
  • Coleman R (2010) Bone targeted therapy for early breast cancer. EJC SUPPLEMENTS, Vol. 8(3) (pp 123-123)
  • Lindman H, Lipatov O, Bondarenko I, Panasci L & Coleman R (2010) RIBBON-1: efficacy of capecitabine-bevacizumab in patients with triple-negative metastatic breast cancer (MBC). EJC SUPPLEMENTS, Vol. 8(3) (pp 204-204)
  • Bundred N, Cramer A, Morris J, Landberg G, Renshaw L, Winter M, Coleman RE, Grassby S, Knox WF & Dixon JM (2010) Randomised placebo controlled trial studying short term biological effects of the combination of letrozole and zoledronic acid on invasive breast cancer. EJC SUPPLEMENTS, Vol. 8(3) (pp 90-91)
  • Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Bliss JM, Coombes RC & Kilburn LS (2010) . BREAST CANCER RES TR, Vol. 124(1) (pp 153-161)
  • Bliss J, Kilburn L, Coleman R, Forbes J, Coates A, Jones S, Jassem J, Delozier T, Andersen J, Paridaens R & Coombes R (2009) . General Session Abstracts
  • Bundred N, Cramer A, Morris J, Landberg G, Renshaw L, Winter M, Coleman R, Grassby S, Knox F & Dixon M (2009) . Poster Session Abstracts
  • Coleman R, Bundred N, De Boer R, Llombarto A, Campbell I, Neven P, Barrios C, Dias R, Miller J & Brufsky A (2009) Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. CANCER RESEARCH, Vol. 69(24) (pp 733S-733S)
  • Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens RJ , Coombes RC et al (2009) Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES).. CANCER RESEARCH, Vol. 69(24) (pp 487S-487S)
  • Bundred NJ, Cramer A, Morris J, Landberg G, Renshaw L, Winter M, Coleman RE, Grassby S, Knox F & Dixon M (2009) Randomised Placebo Controlled Trial Studying Short Term Biological Effects of the Combination of Letrozole and Zoledronic Acid on Invasive Breast Cancer. CANCER RESEARCH, Vol. 69(24) (pp 595S-595S)
  • Banks L, Girgis S, Hodgson S, Liao J, Baffoe G, Kilburn L, Bliss J, Coombes C & Coleman R (2009) (PREMIER POSTER - AWARD CANDIDATE) INTERGROUP EXEMESTANE BREAST CANCER STUDY: REVERSAL OF SKELETAL EFFECTS FOLLOWING WITHDRAWAL OF ENDOCRINE TREATMENTS. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp S280-S280)
  • Dranitsaris G, Coleman R & Gradishar W (2009) Nab-paclitaxel weekly or q3w compared to docetaxel q3w as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
  • Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
  • Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
  • Hadji P, Gnant M, Aapro M, Lipton A & Coleman R (2009) DOSING OF ZOLEDRONIC ACID (ZOL) THROUGHOUT THE TREATMENT CONTINUUM IN PATIENTS (PTS) WITH BREAST CANCER (BC). ANNALS OF ONCOLOGY, Vol. 20 (pp 31-31)
  • Hadji P, Body J, Aapro M, Brufsky A, Coleman R, Guise T, Lipton A & Tubiana-Hulin M (2009) MANAGING AROMATASE INHIBITOR-ASSOCIATED BONE LOSS: PRACTICAL GUIDANCE. ANNALS OF ONCOLOGY, Vol. 20 (pp 32-32)
  • Winter MC, Cross SS, Ingram CE, Jolley IJ, Holen I, Hatton MQ, Horsman JM & Coleman R (2009) ANZAC: A NEOADJUVANT BIOMARKER STUDY EXPLORING THE ANTI-TUMOUR ACTIVITY OF THE ADDITION OF ZOLEDRONIC ACID TO CHEMOTHERAPY IN BREAST CANCER. ANNALS OF ONCOLOGY, Vol. 20 (pp 55-55)
  • Frassoldati A, Brufsky A, Bundred N, Lambert-Falls R, Hadji P, Schenk N, Paija O, Mena R & Coleman R (2009) The effect of zoledronic acid in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trials. BREAST, Vol. 18 (pp S51-S52)
  • Hadji P, Gnant M, Aapro M, Lipton A & Coleman R (2009) Dosing of zoledronic acid (ZOL) throughout the treatment continuum in patients (pts) with breast cancer (BC). BREAST, Vol. 18 (pp S60-S60)
  • Terpos E, Berenson JR, Lipton A, Coleman R & Cook R (2009) High Baseline NTX Predicts for Inferior Survival and Shorter Time to First SRE in Multiple Myeloma. CLIN LYMPHOMA MYELOM, Vol. 9 (pp S55-S56)
  • Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ & Coleman RE (2009) . Poster Session Abstracts
  • Eidtmann H, Bundred NJ, DeBoer R, Llombart A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N & Coleman R (2009) . General Session Abstracts
  • Coleman RE, Banks LM, Girgis S, Vrdoljak E, Fox J, Cawthorn S, Patel A, Coombes C, Bliss JM, Kilburn LS & on Behalf of the IES Group (2009) . Poster Session Abstracts
  • Coleman RE, Banks LM, Girgis S, Vrdoljak E, Fox J, Cawthorn S, Patel A, Coombes C, Bliss JM, Kilburn LS & Grp IES (2009) Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study. CANCER RESEARCH, Vol. 69(2) (pp 144S-144S)
  • Eidtmann H, Bundred NJ, DeBoer R, Llombart A, Davidson N, Neven P, Von MG, Miller J, Schenk A & Coleman R (2009) The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. CANCER RESEARCH, Vol. 69(2) (pp 74S-74S)
  • Ottewell PD, Leftey DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 200S-201S)
  • Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ & Coleman RE (2009) The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumor activity in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 330S-330S)
  • Coleman RE (2009) . BREAST CANCER RESEARCH, Vol. 11 (pp S7-S7)
  • Frassoldati A, Brufsky A, Bundred N, Lambert-Falls R, Hadji P, Mena R, Paija O & Coleman R (2008) THE EFFECT OF ZOLEDRONIC ACID ON AROMATASE INHIBITOR (AI) ASSOCIATED BONE LOSS (AIBL) IN POSTMENOPAUSAL WOMEN (PMW) WITH EARLY BREAST CANCER (EBC) RECEIVING ADJUVANT LETROZOLE: 24 MONTHS (MOS) INTEGRATED FOLLOW-UP OF THE Z-FAST/ZO-FAST TRIALS. ANNALS OF ONCOLOGY, Vol. 19 (pp 78-78)
  • Coleman R, Cook R, Saad F, Hirsh V, Major P, Dias R & Lipton A (2008) EFFECTS OF ZOLEDRONIC ACID (ZOL) ON SURVIVAL IN PATIENTS WITH METASTATIC BONE DISEASE AND HIGH BONE TURNOVER: RESULTS FROM A META-ANALYSIS. ANNALS OF ONCOLOGY, Vol. 19 (pp 276-276)
  • Ottewell P, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in sub-cutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. EJC SUPPLEMENTS, Vol. 6(9) (pp 18-18). Lyon, FRANCE, 5 July 2008 - 8 July 2008.
  • Cook RJ, Hirsh V, Major PP, Saad F, Dias R, Lipton A & Coleman RE (2008) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
  • Dranitsaris G, Lidgren M, Lundkvist J & Coleman RE (2008) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
  • Coleman RE & Grp ATACT (2008) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
  • Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM, Kennedy MJ, Coleman RE, Leonard RC, Earl HM & Collaborators TT (2008) tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
  • Brown JE, Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR & Coleman RE (2008) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
  • Evans TR, Yellowlees A, Devine I, Earl HM, Cameron DA, Hutcheon AW, Coleman RE, Crown JP, Leonard RC & Mansi JL (2008) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
  • Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
  • Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA & Grp, ZF&ZFS (2008) . ONCOLOGIST, Vol. 13(5) (pp 503-514)
  • Dranitsaris G, Lidgren M, Lundkvist J & Coleman R (2008) Nab-paclitaxel or docetaxel; As alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): A cost utility analysis in five European countries. VALUE HEALTH, Vol. 11(3) (pp A71-A71)
  • Dranitsaris G, Lidgren M, Lundkvist J & Coleman R (2008) Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK). EJC SUPPLEMENTS, Vol. 6(7) (pp 67-67)
  • Coleman R (2008) Recent developments in the management of metastatic bone disease. EJC SUPPLEMENTS, Vol. 6(7) (pp 108-108)
  • Coleman R, Brown J & Cook R (2008) Serum lactate dehydrogenase (LDH) is a significant prognostic variable for survival in patients with metastatic breast cancer - a multivariate analysis. EJC SUPPLEMENTS, Vol. 6(7) (pp 189-189)
  • Burkinshaw R, Brufsky A & Coleman R (2008) Antitumor properties of bisphosphonates and possible prevention of bone metastases in breast cancer. EJC SUPPLEMENTS, Vol. 6(7) (pp 129-129)
  • Murray LJ, Ramakrishnan S, Purohit OP, Manifold IH & Coleman RE (2008) Adjuvant trastuzumab in routine clinical practice - the Sheffield experience and impact of cardiac monitoring guidelines on treatment delivery. EJC SUPPLEMENTS, Vol. 6(7) (pp 124-124)
  • Lefley DV, Holen I, Coleman RE & Ottewell PD (2008) . BREAST CANCER RESEARCH, Vol. 10 (pp S40-S40)
  • Ottewell PD, Lefley DV, Coleman RE & Holen I (2008) . BREAST CANCER RESEARCH, Vol. 10 (pp S40-S41)
  • Coleman R, Cook R, Saad F, Hirsh V, Major P, Dias R & Lipton A (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S86-S86)
  • Coleman R, Brown J & Cook R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S78-S79)
  • Brown J, Cook R & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S79-S79)
  • Lester J, Dodwell D, Purohit O, Gutcher S, Ellis S, Thorpe R, Horsman J, Brown J, Hannon R & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S51-S51)
  • Lipton A, Body JJ, Cookc R & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S53-S53)
  • Singh S, Cuzick J, Ferguson S, Blake G, Truscott J, Coleman R, Eastel R & Howell A (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S53-S54)
  • Hirsh V, Major P, Lipton A, Cook R, Langer C, Smith M, Brown J & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S85-S85)
  • Winter M, Thorpe H, Burkinshaw R, Beevers S & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S55-S56)
  • Ottewell P, Coleman R & Holen I (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S62-S62). Heriot Watt Univ, Edinburgh, SCOTLAND, 29 June 2008 - 2 July 2008.
  • Burkinshaw R, Winter M, Thorpe H, Pedlar J & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S75-S76)
  • Coleman RE & AZURE Investigators (2008) The AZURE trial for prevention of bone metastases. CLIN EXP METASTAS, Vol. 25 (pp 19-19)
  • Coleman RE (2008) New diagnostic and therapeutic approaches for cancer induced bone disease. CALCIFIED TISSUE INT, Vol. 82 (pp S24-S24)
  • Deboerr R, Eidtmann H, Pinotti G, Miller J, Schenk N, Dias R & Coleman R (2007) The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S36-S36)
  • Eastell R, Coleman R, Mansel R, Bianco A, Nagykalnai T, Cuzick J & ATAC Trialists Grp (2007) The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S109-S109)
  • Lipton A, Cook R, Major P, Smith M & Coleman R (2007) Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
  • Singh S, Cuzick J, Edwards R, Blake G, Truscott J, Coleman R, Eastell R & Howell A (2007) Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S9-S9)
  • Woodward J, Lefley D, Cross N, Ottewell PD, Buttle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A97-A97)
  • Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
  • Terpos E, Cook R, Coleman R, Lipton A & Berenson J (2007) Predictors for skeletal-related events in patients with advanced multiple myeloma. BLOOD, Vol. 110(11) (pp 443A-444A)
  • Berenson J, Cook R, Lipton A, Coleman R & Terpos E (2007) Increased levels of urinary N-telopeptide of type I collagen correlate with reduced survival in patients with advanced multiple myeloma. BLOOD, Vol. 110(11) (pp 449A-449A)
  • Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS , Coleman R et al (2007) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(28) (pp 4431-4437). San Antonio, TX, 10 December 2006 - 14 December 2006.
  • Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R & Aapro M (2007) Updated International Society of Geriatric Oncology (SIOG) recommendations for the use of bisphosphonates in elderly cancer patients with bone metastases. EJC SUPPLEMENTS, Vol. 5(4) (pp 174-174)
  • Dranitsaris G, Coleman R & Gradishar WJ (2007) Nab-Paclitaxel weekly or Q3Wks compared to Docetaxel Q3Wks as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. EJC SUPPLEMENTS, Vol. 5(4) (pp 219-219)
  • Lipton A, Cook RJ, Major P, Smith MR & Coleman RE (2007) Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors. EJC SUPPLEMENTS, Vol. 5(4) (pp 58-58)
  • Major P, Hirsh V, Lipton A, Cook RJ & Coleman RE (2007) Zoledronic Acid (ZOL) treatment may improve survival in patients with lung cancer and high baseline N-telopeptide levels: a multivariate Cox regression analysis. EJC SUPPLEMENTS, Vol. 5(4) (pp 94-94)
  • Coleman RE, Thorpe H, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Cousins J, Burkinshaw R & AZURE Investigators (2007) Tolerability of zoledronic acid - first safety data from the AZURE Trial (BIG01/04). EJC SUPPLEMENTS, Vol. 5(3) (pp 15-15)
  • Coleman R (2007) Role of bisphosphonates in cancer management. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1106-1106)
  • Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111)
  • Woodward JKL, Lefley DV, Cross NA, Ottewell PD, Battle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1142-1143)
  • Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D & Coleman RE (2007) Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
  • Scott E, Daley A, Woodroofe N, Coleman R, Powers H, Mutrie N, Siddall V, Crank H & Saxton JM (2007) The effect of a lifestyle intervention on body weight, psychological health status, and risk factors associated with disease recurrence in women recovering from breast cancer treatment: Study protocol and interim findings. JOURNAL OF NUTRITION, Vol. 137(1) (pp 284S-284S)
  • Van Pozanki C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2007) Osteoprotegerin (OPG) expression in breast tumors and bone metastases. INT J BIOL MARKER, Vol. 22(1) (pp 83-84)
  • Lipton A, Cook R, Coleman RE, Major P, Terpos E, Body J, Smith MR, Brown J & Garnero P (2007) Normalization of bone markers and improved survival during zoledronic acid therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
  • Verrill MW, Lee J, Cameron DA, Agrawal R, Coleman RE, McAdam K, Wardley A, Bowman A, Ferrigan L & Yellowlees A (2007) Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
  • Coleman R (2006) The use of bisphosphonates in elderly cancer patients: SIOG guidelines. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, Vol. 60 (pp S16-S16)
  • Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ , Guise TA et al (2006) . CLINICAL CANCER RESEARCH, Vol. 12(20) (pp 6209S-6212S)
  • Lipton A, Cook R, Coleman R, Major P & Shirina N (2006) Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors. ANNALS OF ONCOLOGY, Vol. 17 (pp 254-255)
  • Steger GG, Body JJ, Solal-Celigny P, Berardi R, Gascon P, Fan M, Kinsey A, Jun S & Coleman R (2006) Denosumab suppresses bone turnover markers in breast cancer patients (PTS) with bone metastases (METS) naive to intravenous bisphosphonates (IV BP) regardless of antineoplastic treatment. ANNALS OF ONCOLOGY, Vol. 17 (pp 288-289)
  • Shirina N, Coleman RE & Chen YM (2006) Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 24(18) (pp 475S-475S)
  • Coleman RE & ATAC Trialists' Grp (2006) Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 24(18) (pp 5S-5S)
  • Coleman R (2006) Cancer and bone disease. OSTEOPOROSIS INTERNATIONAL, Vol. 17 (pp 363-364)
  • Burkinshaw R, Thorpe H, Pollard S, Bell R, Dodwell D, Cameron D, Coleman R & AZURE Investigators (2006) . BONE, Vol. 38(3) (pp S70-S71)
  • Coleman RE & Chen YM (2006) Zoledronic acid provides an enhanced reduction in skeletal-related events in patients with more than three metastatic bone lesions. CANCER TREATMENT REVIEWS, Vol. 32 (pp S51-S51)
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of zoledronic acid and doxorubicin in breast cancer models in vivo. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30)
  • Holen I, Hannon RA, Ellis SP, Coleman RE & Brown JE (2006) Effects of clodronate on serum osteoprotogerin (OPG) in patients with metastatic bone disease. CANCER TREATMENT REVIEWS, Vol. 32 (pp S40-S40)
  • Lester JE, Gutcher SA, Ellis S, Thorpe R, Horsman J, Brown JE, Purohit OP, Dodwell D & Coleman RE (2006) The ARIBON study: Reversal of anastrozole (Arimidex) induced bone loss with oral monthly ibandronate (Bondronat) treatment during adjuvant therapy for breast cancer.. CANCER TREATMENT REVIEWS, Vol. 32 (pp S48-S49)
  • Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O & Coleman RE (2006) Infrequent zoledronic acid produces sustained increases in bone mineral density (BMD) in patients with cancer treatment induced bone loss (CTIBL). CANCER TREATMENT REVIEWS, Vol. 32 (pp S19-S19)
  • Lester J, Horsman J, Purohit OP, Brown JE & Coleman RE (2006) . BONE, Vol. 38(3) (pp S79-S79)
  • Lester JE, Penty L, Brown JE, Radstone C, Purohit OP & Coleman RE (2006) . BONE, Vol. 38(3) (pp S79-S80)
  • Neville-Webbe HL, Lefley D, Coleman RE & Holen I (2006) . BONE, Vol. 38(3) (pp S58-S59)
  • Body JJ, Lichinitser M, Coleman RE & Bergstrom B (2006) . BONE, Vol. 38(3) (pp S69-S69)
  • Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit O & Coleman RE (2006) . BONE, Vol. 38(3) (pp S70-S70)
  • Van Poznak C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2006) . BONE, Vol. 38(3) (pp S31-S32)
  • Holen I, Patel R, Lefley DV, Webbe HLN, Coleman RE & Woodward JKL (2006) . BONE, Vol. 38(3) (pp S51-S52)
  • Michailidou M, Neville-Webbe HL, Evans CA, Brown NJ, Coleman RE & Holen I (2006) . BONE, Vol. 38(3) (pp S57-S58)
  • Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC & Bekker P (2006) . CLINICAL CANCER RESEARCH, Vol. 12(4) (pp 1221-1228)
  • Michailidou M, Brown N, Coleman RE & Holen I (2006) . BREAST CANCER RESEARCH, Vol. 8 (pp S18-S18)
  • Holen I, Neville-Webbe H & Coleman RE (2006) . BREAST CANCER RESEARCH, Vol. 8 (pp S4-S4)
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) . BREAST CANCER RESEARCH, Vol. 8 (pp S17-S17)
  • Bhalla S, Hibbert C, Chetty M, Poole C, Miles D, Coleman R, Bruce G, Beard S & Watkins J (2006) An evaluation of the clinical and cost-effectiveness of combination chemotherapy with gemcitabine plus paclitaxel for the treatment of metastatic breast cancer (MBC) in the UK from an NHS perspective.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S232-S232)
  • Coleman R, Thorpe H, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Cousins J & Burkinshaw R (2006) Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy - first safety data from the AZURE trial (BIG01/04).. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S107-S107)
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and anti-resorptive agents in vitro and in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S290-S290)
  • Poole CJ, Hiller L, Howard HC, Loi S, Dunn JA, Canney P, Wardley AM, Crown JP, Coleman RE, Verrill MW , Ellis PA et al (2006) Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S114-S114)
  • Cook RJ, Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Chen YM & Hei YJ (2005) Prognostic significance of biochemical markers of bone metabolism in patients with bone lesions from multiple myeloma (MM).. BLOOD, Vol. 106(11) (pp 335B-335B)
  • Lipton A, Coleman RE, Major P, Brown JE, Lee KA, Smith M, Saad F, Chen YM, Hei YJ & Cook R (2005) Baseline N-telopeptide levels correlate with risk of skeletal morbidity in patients with multiple myeloma during zoledronic acid therapy.. BLOOD, Vol. 106(11) (pp 964A-965A)
  • Banks L, Girgis S, Coleman R, Porter L, Baffoe G, Price D, Hall E, Bliss J & Coombes C (2005) Skeletal effect of exemestane in patients with breast cancer.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S327-S327)
  • Woodward JKL, Neville-Webbe H, Coleman RE & Holen I (2005) The effects of zoledronic acid and doxorubicin in combination on breast cancer cell invasion in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(7) (pp 1299-1299)
  • Lipton A, Hei Y, Coleman R, Major P & Cook R (2005) Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(16) (pp 11S-11S)
  • Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit OP, Hancock B & Coleman R (2005) Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss (CTIBL)?. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(16) (pp 734S-734S)
  • Coleman RE (2005) Breast cancer and bone. BONE, Vol. 36 (pp S114-S115)
  • Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M , Crown J et al (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(13) (pp 2988-2995)
  • Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S , Trudeau M et al (2005) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(9) (pp 1859-1866)
  • Aapro M, Schulman C, Zheng M & Coleman R (2005) Onset of time to first skeletal-related event in patients with advanced cancer metastatic to bone and the clinical benefit of bisphosphonates. CANCER TREATMENT REVIEWS, Vol. 31 (pp S24-S24)
  • Lipton A, Rosen L, Kohno N, Coleman R, Zheng M & Milton S (2005) Zoledronic acid provides long-term reduction of bone pain in patients with bone metastases secondary to breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S29-S30)
  • Coleman R (2005) Developing more rational use of bisphosphonates in malignancy. CANCER TREATMENT REVIEWS, Vol. 31 (pp S19-S19)
  • Burkinshaw R, Bell R, Dodwell D, Cameron D, Coleman R & AZURE Investigators (2005) The AZURE trial - Does adjuvant zoledronic acid reduce recurrence in patients with high-risk localised breast cancer?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S46-S47)
  • Woodward J, Coleman R, Neville-Webbe H & Holen I (2005) The combined effects of zoledronic acid (ZOL) and doxorubicin (DOX) on breast cancer cell invasion in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S43-S43)
  • Lichinitser MR, Coleman RE, Tjulandin SA, Bergstrom B & Body JJ (2005) Non-inferiority of oral ibandronate to intravenous zoledronic acid for reducing markers of bone turnover in metastatic breast cancer patients. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S259-S259)
  • Body JJ, Lichinitser MR, Tjulandin SA, Coleman RE & Bergstrom B (2005) Safety of oral ibandronate and intravenous zoledronic acid in breast cancer patients with metastatic bone disease. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S260-S260)
  • Hei YJ, Saad F, Coleman RE & Chen YM (2005) Fractures negatively affect survival in patients with bone metastases from breast cancer. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S260-S260)
  • Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Porter LS, Snowdon CF, Hall E, Bliss JM, Coombes RC & IES (2005) Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S233-S233)
  • Lipton A, Hei YJ, Coleman RE, Major P, Smith M, Cook RJ & Milton S (2005) Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S129-S129)
  • Lester JE, Brown JE, Ellis SP, Gutcher S, Horsman JM & Coleman RE (2005) The use of point of care devices for the monitoring of urinary NTX levels in metastatic breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S52-S53)
  • Brown JE, Ellis SP, Silcock P, Gutcher SA, Radstone C, Blumsohn A, Hancock BW, Hatton MQ & Coleman RE (2005) Do long-term cancer survivors, treated for testicular cancer or lymphoma, suffer chemotherapy-induced bone loss?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S46-S46)
  • Ellis SP, Brown JE, Everard JE, Neville-Webbe HL, Hancock BW & Coleman RE (2005) A study to determine whether the bisphosphonate zoledronic acid can be shown to exert a direct anti tumour effect in vivo. CANCER TREATMENT REVIEWS, Vol. 31 (pp S48-S49)
  • Lester JE, Horsman JM, Mori S, Dodwell D & Coleman RE (2005) Breast cancer and treatment induced bone loss questionnaire. CANCER TREATMENT REVIEWS, Vol. 31 (pp S52-S52)
  • Evans CA, Neville-Webbe HL, Coleman RE & Holen I (2005) Differential induction of apoptosis following sequential treatments using cytotoxic drugs and zoledronic acid. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36)
  • Cross SS, Yang Z, Woodward JKL, Balasubramanian SP, Reed MWR, Coleman RE, Brown NJ & Holen I (2005) Tumour endothelial cells express osteoprotegerin (OPG) - A potential role in tumour angiogenesis?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S37-S38)
  • Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S41-S41)
  • Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S28-S28)
  • Brown JE, Ellis SP, Gutcher SA, Purohit OP, Turner L, Neville-Webbe HL & Coleman RE (2005) Using bone turnover markers to direct bisphosphonate therapy: Is this a feasible approach?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S30-S30)
  • Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A & Kaye SB (2004) . JNCI Journal of the National Cancer Institute, Vol. 96(22) (pp 1682-1691)
  • Conte P & Coleman R (2004) . Seminars in Oncology, Vol. 31 (pp 59-63)
  • Coleman R, Heidenreich A & Bell R (2004) . Seminars in Oncology, Vol. 31 (pp 83-86)
  • Coleman R (2004) Expanding indications for bone-specific treatments in oncology. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1568-1569)
  • Peterson MC, Martin SW, Stouch BJ, Chen D, Bauhman S, Holloway DL, Rasmussen AS, Lipton A, Coleman R, Body JJ , Bekker PJ et al (2004) Serum concentrations of AMG 162 were maintained and bone resorption was suppressed for 3 months following a single subcutaneous dose in patients with breast cancer-related bone metastases. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1595-1595)
  • Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Zoledronic acid (ZOL) in combination with doxorubicin (DOX) has synergistic effects on apoptosis of breast cancer cells (BCCs) in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1598-1598)
  • Brown JE, Ellis S, Gutcher S, Lester JE, Turner L, Purohit OP, Hancock BW & Coleman RE (2004) Effect of an annual infusion of zoledronic acid on bone mineral density in cancer survivors following antineoplastic therapy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
  • Cook RJ, Coleman RE, Saad F, Smith M, Lipton A, Lee KA, Brown JE, Zheng M, Hei YJ & Major P (2004) The predictive value of bone resorption and formation markers in patients with prostate cancer metastatic to bone. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
  • Brown JE, Cook RJ, Major P, Lipton A, Lee KA, Zheng M, Hei YJ & Coleman RE (2004) The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
  • Ellis SP, Brown JE, Gutcher SA, Hancock BW, Hatton MQ, Rigby AS & Coleman RE (2004) An investigation of the long-term effects of chemotherapy on bone in male long-term cancer survivors. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1587-1587)
  • Body JJ, Coleman RE, Lipton A, Murphy R, Holloway DL, Bekker PJ & DePaoli AM (2004) Rapid, profound, and prolonged suppression of bone turnover with a single SC dose of AMG 162 in women with breast cancer metastatic to bone. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1593-1593)
  • Coleman R & ATAC Trialists Grp (2004) Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 68S-68S)
  • Peterson MC, Martin SW, Stouch B, Chen D, Holloway DL, Body JJ, Lipton A, Coleman R & Bekker PJ (2004) Pharmacolkinetics (PK) and pharmacodynamics (PD) of AMG 162, a fully human monoclonal antibody to receptor activator of NF kappa B ligand (RANKL), following a single subcutaneous dose to patients with cancer-related bone. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 755S-755S)
  • Brown JE, McCloskey E, Dewar JA, Body JJ, Cameron DA, Purohit OPK, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 743S-743S)
  • Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Crown J, Leonard RC & Mansi JL (2004) Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 8S-8S)
  • Poole CJ, Howard HC, Hiller L, Dunn JA, Wardley AM, Bowman A, Coleman RE, Fernando IN, Ritchie DM & Earl HM (2004) A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in 'tAnGo': A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 81S-81S)
  • Herbertson RA, Hatton MQ, Coleman J & Coleman RE (2004) A retrospective study of the management and outcome of patients with stage 1 (marker negative) teratoma. BRITISH JOURNAL OF CANCER, Vol. 91 (pp S39-S39)
  • Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Combined treatments of breast cancer cells using bisphosphonates and doxorubicin. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(6) (pp 1035-1035)
  • Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and paclitaxel have synergistic antitumor activity and induce apoptotic tumor cell death at clinically relevant concentrations. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S132-S132)
  • Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Sequential exposure of breast cancer cells to cytotoxic agents and zoledronic acid induces synergistic increase in apoptotic cell death.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S72-S72)
  • Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Presence of BRCA1 gene enhances levels of apoptosis induced by combination treatment with doxorubicin (DOX) and zoledronic acid (ZOL).. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S73-S73)
  • Coleman RE, Banks LM, Hall E, Price D, Girgis S, Bliss JM & Coombes RC (2004) Intergroup Exemestane Study: 1 year results of the bone sub-protocol. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S35-S35)
  • Van Poznac C, Cross SS, Saggese M, Lippitt JM, Hudis C, Coleman RE & Holen I (2004) Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29)
  • Evans A, Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and TRAIL induce synergistic increase in apoptotic tumor cell death. BONE, Vol. 34 (pp S56-S56)
  • Neville-Webbe H, Coleman RE & Holen I (2004) Paclitaxel and zoledronic acid induce synergistic increase in apoptotic tumour cell death at clinically relevant concentrations. BONE, Vol. 34 (pp S67-S68)
  • Van Poznak CH, Cross SS, Hudis C, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin expression correlates with ER/PR status in human breast tumors.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S310-S310)
  • Goodhart LM, Brown JE, Ellis S, Gutcher S, Purohit OP & Coleman RE (2003) Development of a touch screen questionnaire approach for measurement of pain assessment scales in cancer patients with bone metastasis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S67-S67)
  • Khan FK, Everard J, Ahmed S, Coleman RE, Aitken M & Hancock BW (2003) Low risk persistent gestational trophoblastic disease treated with low dose methotrexate. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S18-S18)
  • Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD , Nakanishi A et al (2003) . CANCER, Vol. 97(3) (pp 887-892)
  • Coleman R (2003) . European Journal of Cancer Supplements, Vol. 1(6) (pp 299-306)
  • Coleman RE (2003) Treatment of Skeletal Complications of Cancer with Zoledronic Acid (Zometa): Editorial. Seminars in Oncology, Vol. 29(6 SUPPL. 21) (pp 1-2)
  • Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport B, Nooij M, Delhaye F, Miles D, Sulkes A , Hamilton A et al (2003) . CANCER, Vol. 97(1) (pp 40-45)
  • Van Poznak CH, Cross SS, Hudis C, Norton L, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) are expressed in human breast tumors.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 82 (pp S162-S162)
  • Fernie NL, Zekri J, Leonard RCF, Coleman RE & Cameron DA (2003) Exemestane in metastatic breast cancer: effective therapy after 3(rd) generation aromatase inhibitor failure.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 82 (pp S104-S104)
  • Coleman RE (2002) . American Journal of Clinical Oncology, Vol. 25 (pp S1-S2)
  • Coleman RE, Rosen LS, Gordon D, Major P, Kaminski M, Apffelstaedt J, Howell A, Chen BL & Seaman JJ (2002) Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 76 (pp S95-S95)
  • Holen I, Wells JM, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Jagdev SP, Hamdy FC & Eaton CL (2002) The role of osteoprotegerin in breast and prostate cancer. J BONE MINER RES, Vol. 17(7) (pp 1339-1339)
  • Brown JE, Ellis S, Gutcher S, Turner L, Purohit OP & Coleman RE (2002) Bone marker directed bisphosphonate therapy in metastatic bone disease. BRIT J CANCER, Vol. 86 (pp S19-S19)
  • Abdallah SY, Everard J, Ingram CE, Nakielny R, Coleman RE & Hancock BW (2002) An evaluation of patients with persistent gestational trophoblastic disease (PGTD) with lung metastases only on chest X-ray or CT scan of the chest, is there extra benefit from CT scan?. BRIT J CANCER, Vol. 86 (pp S45-S45)
  • Bhala N, George J, Coleman JM, Radstone CR, Horsman JM, Hancock BW, Hatton MQ & Coleman RE (2002) Management of patients with advanced germ cell tumours (GCT): Is there a role for POMB-ACE?. BRIT J CANCER, Vol. 86 (pp S65-S65)
  • Brown JE, Ellis S, Gutcher S, Thompson C, Purohit OP & Coleman RE (2002) Relationship between bone resorption and skeletal events in metastatic bone disease. BONE, Vol. 30(3) (pp 47S-47S)
  • Brown JE, Ellis S, Gutcher S, Turner L, Purohit OP & Coleman RE (2002) Bone marker directed bisphosphonate treatment. A pilot study to determine feasibility. BONE, Vol. 30(3) (pp 47S-47S)
  • Holen I, Croucher PI, Evans AC, Lippitt JM, Hamdy FC, Coleman RE & Eaton CL (2002) OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S)
  • Lipton A, Coleman RE, Diel IJ & Mundy G (2001) . Seminars in Oncology, Vol. 28(4I) (pp 1-1)
  • Nevin J, Silcocks P, Hancock B, Coleman R, Nakielny R & Lorigan P (2000) . Gynecologic Oncology, Vol. 78(2) (pp 92-96)
  • Ahmed SI, George J, Coleman JM, Radstone CR, Horsman JM, Hatton MQ & Coleman RE (2000) Ten year review of survival of patients with advanced non-seminomatous germ cell tumours (NSGCT): The Weston Park experience. BRIT J CANCER, Vol. 83 (pp 78-78)
  • Ahmed SI, Higgins J, Briggs T, Pledge SD & Coleman RE (2000) Preliminary results of a phase II study of weekly paclitaxel and etopophos chemotherapy in patients with relapsed ovarian carcinoma. BRIT J CANCER, Vol. 83 (pp 79-79)
  • Coleman RE (1998) Adjuvant therapy of breast cancer - A review. Imaging, Vol. 10(1) (pp 28)
  • Coleman RE (1998) Developments in the palliation of metastatic bone disease. EUR J CANCER, Vol. 34 (pp S90-S90)
  • Coleman RE, Howell A, Eggleton SPH, Maling SJ & Miles DW (1998) An open phase II study of Taxotere in 42 patients with liver metastases from breast cancer. ANN ONCOL, Vol. 9 (pp 15-15)
  • Dobson LS, Lorigan PC, Coleman RE & Hancock BW (1998) Toxicity associated with etoposide and Dactinomycin (EA) for methotrexate (MTX) resistant, low risk persistent trophoblastic disease (PTD) and EA with MTX (MEA) for high risk PTD. ANN ONCOL, Vol. 9 (pp 66-67)
  • Broadhead TJ, Gillespie AM, Coleman RE, Owen J, Skelton L, Stephens S, Farnsworth A, Sopwith M & Chan SY (1998) CMB-401: A cytotoxic immunoconjugate for targeted therapy of epithelial ovarian cancer. ANN ONCOL, Vol. 9 (pp 85-85)
  • Gillespie AM, Coleman RE & Hancock BW (1998) Is computed tomography necessary to evaluate pulmonary metastases in patients with persistent trophoblastic disease?. BRIT J CANCER, Vol. 78 (pp 42-42)
  • Dobson LS, Clive S, Dawson L, Anderson A, Leonard RCF, Kunkler I & Coleman RE (1998) Treosulphan monotherapy for metastatic breast cancer - A phase II study.. BRIT J CANCER, Vol. 78 (pp 42-42)
  • Broadhead TJ, Gillespie AM, Coleman RE, Owen J, Skelton L, Stephens S, Farnsworth A, Sopwith M & Chan SY (1998) CMB-401 - A new agent for immunotherapy of epithelial ovarian cancer: Immune response and pharmacokinetics. BRIT J CANCER, Vol. 78 (pp 44-44)
  • Gillespie AM, Siddiqui N, Coleman RE & Hancock BW (1998) Does central nervous system chemoprophylaxis have a role in the management of gestational trophoblastic disease?. BRIT J CANCER, Vol. 78 (pp 13-13)
  • Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M & Coleman RE (1998) Phase I study of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.. BRIT J CANCER, Vol. 78 (pp 20-20)
  • Hough RE, Browne S, El-Helw LM, Coleman RE, Robinson MH & Lorigan PC (1998) High dose chemotherapy for soft tissue Ewing's sarcomas.. BRIT J CANCER, Vol. 78 (pp 42-42)
  • Zekri J & Coleman RE (1998) Possible adverse effects of curative chemotherapy on bone mass in men: Use of bone ultrasound to evaluate bone architecture. BRIT J CANCER, Vol. 78 (pp 12-12)
  • ElHelw L, Lorigan PC, Coleman RE & Hancock BW (1997) The vedex regimen: An effective and well tolerated palliative treatment for non-Hodgkin's lymphoma (NHL). EUR J CANCER, Vol. 33 (pp 1201-1201)
  • Coleman RE (1996) Recent developments in the medical management of bone metastases. XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2 (pp 105-113)
  • Rustin GJS, Crawford SM, Coleman RE, Lambert J, Ledermann JA, Soukop M, Karp S, Phillips RH, Habboubi N & Meely K (1995) Trial of oral Hexalen for relapsed ovarian carcinoma [OV/CA]: Comparison of CA125 and eortc response definitions. EUR J CANCER, Vol. 31A (pp 513-513)
  • Lorigan PC, Nevin J, Radstone C, Coleman RE & Hancock BW (1995) Etoposide and actinomycin D (EA) for methotrexate (MTX) resistant, low risk, persistent gestational trophoblastic disease (GTD) and EA with MTX (MEA) for high risk GTD. EUR J CANCER, Vol. 31A (pp 1168-1168)
  • Coleman RE, Paterson AHG, Conte PF, Tyrrell CJ, Walls J, Henderson MA, Bundred NJ, Murray R, Fife K, Blamey RW & Rubens RD (1994) . The Breast, Vol. 3(3) (pp 181-185)

Preprints

  • Rugo HS, Poznak CHV, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Alonso EV, Naume B, Brain E , Siegel JM et al (2022) , Research Square Platform LLC.
Research group

PhD Students

  • Dr Matt Winter
  • Dr Omar Din
  • Dr Emma Woodward

Links